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1 The Institute – an Overview 
The Ludwig Boltzmann Institute for Health Technology Assessment (LBI-
HTA) was formally founded on March 2006 and is intended to operate for a 
period of seven years. Therefore 2009 was the 4th year of the institute’s opera-
tional activity. Evaluation regarding its continuation until 2013 took place 
on May 7th and 8th 2009. Four international experts appraised the operation 
of the LBI-HTA on the basis of explicit criteria preassigned by the Ludwig 
Boltzmann Society. 
1.1 Budget 
The annual budget of the Ludwig Boltzmann Institute for Health Technol-
ogy Assessment - funded by the Ludwig Boltzmann Society and institutional 
partners – was € 870.000 in the year 2009. Additional third party amounted 
to additional 4,3% of the budget. 
1.2 Partners 
In line with the research policy of the Ludwig Boltzmann Society, the insti-
tute focuses on translational research. The research programme requires 
strong emphasis on applicable short term or medium term results. By setting 
up partnerships between research-producing and research-applying organi-
sations or institutions, the quick transfer of research results is guaranteed. 
Partner-institutions of the Ludwig Boltzmann Institute for Health Technol-
ogy Assessment are actors in health care administration, responsible bodies 
of public hospitals and private universities.  
TILAK/ Tiroler Landeskrankenanstalten GmbH 
Anichstraße 35, 6020 Innsbruck 
http://www.tilak.at 
KAGES/ Steiermärkische Krankenanstalten GmbH 
Stiftingtalstraße 4-6, 8010 Graz 
http://www.kages.at 
 
2009:  
4th year of existence 
evaluation regarding 
continuation until 2013 
total budget 
translational research: 
partners apply results 
institutional partners 
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AUVA/ Allgemeine Unfallversicherungsanstalt 
Adalbert-Stifterstraße 65, 1201 Wien  
http://www.auva.at 
BMG/ Bundesministerium für Gesundheit  
Radetzkystraße 2, 1030 Wien  
http://www.bmg.gv.at 
UMIT/ Private Universität für Gesundheitswissenschaften, Medizi-
nische Informatik und Technik 
Institut für Public Health, Medical Decision Making und HTA 
Eduard Wallnöfer-Zentrum I, 6060 Hall  
http://www.umit.at 
PMU/ Paracelsus Medizinische Privatuniversität 
Institut für Public Health  
Ignaz Harrer Straße 79, 5020 Salzburg 
http://www.pmu.ac.at 
HVB/ Hauptverband der österreichischen Sozialversicherungsträger 
(2008-2013) 
Kundmanngasse 21, 1030 Wien 
http://www.hauptverband.at 
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1.3 Committees 
The LBI-HTA is supported by two committees, namely the Board of Trus-
tees and the Scientific Advisory Group (SAG). 
Figure 1.3-1: Organigramm 
 
Whereas the LBI-HTA’s research programme provides a general methodo-
logical background, agenda setting for current projects is the task of the 
Board of Trustees, which is composed of one representative from each insti-
tutional partner. 
 
KAGES:  
Dr. August Gomsi (Chair) 
TILAK:  
Univ. Prof. Dr. Wolfgang Buchberger 
AUVA:  
Univ. Prof. Dr. Hartmut Pelinka (until 01/06/2009) 
Dr. Andreas Greslehner (since 01/06/2009) 
BMG:  
Dr. Wolfgang Ecker 
board members 
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UMIT:  
Univ. Prof. Dr. Uwe Siebert 
PMU:  
Dr. Markus Schwarz (until summer 2009) 
Dr. Christine Rühle (since summer 2009) 
LBG:  
Mag. Claudia Lingner 
HVB:  
Dr. Gottfried Endel 
Board meetings 2009: 
b 1st Board meeting: 07/05/2009 
b 2nd Board meeting: 06/10/2009 
The first board meeting in 2009 dealt with the financial report and the hu-
man resources development at the LBI-HTA in the year 2009/2010.  Apart, 
fruitful and profitable discussions took place about the evaluation of the in-
stitute, the position of the LBI-HTA within the national context, internal re-
organisation processes and the institute’s future perspectives. Consequently, 
ongoing projetcs and the programme for the year 2009/2010 were presented 
to the board members.  
Since the meeting was arranged - intentionally - at the same time as the 
evaluation took place, the evaluators had the opportunity to exchange (2- 
hours “hearing”) with the board members on their perspectives on their spe-
cific benefits being institutional partners and on HTA implementation in 
Austria in general. 
During the second board meeting in 2009 the director reported about the in-
ternal evaluation process, the prolongation of partners’ contracts and the 
budget 2009. Furthermore, particular projects were discussed in detail.  
 
The Scientific Advisory Group (SAG) gives scientific support and is selected 
– with equal weighting – by the Ludwig Boltzmann Society and the members 
of the Board of Trustees. The SAG is composed of the following member: 
b Univ. Prof. Dr. Norman Waugh/ UK 
b Univ. Prof. Dr. Alistair Gray/ UK 
b Univ. Prof. Dr. Jürgen Windeler/ D 
b Univ. Prof. Dr. Finn Borlum Kristensen/ DK 
b Dr. Dagmar Lühman/ D 
 
The third meeting of the Scientific Advisory Group took place at the LBI-
HTA on 08/05/2009, also at the same time as the evaluation took place. The 
director of the LBI-HTA gave a presentation on activities of the past three 
years. In addition, there was a discussion about the role of the Scientific Ad-
1st board meeting  
2009:  
07/05  
2nd board meeting 
2009:  
06/10 
members of the 
Scientific Advisory 
Group  
3rd meeting of the 
Scientific Advisory 
Group: 08/05 
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visory Group in the project-review process. Furthermore, some LBI-HTA re-
searchers presented selected projects which had a high level of political im-
pact and relevance, and highlighted the need for transparency in all the 
HTA-process. These were: 
b “Development of an HPV decision aid” – Brigitte Piso 
b “Rapid assessments of single medical services (MELs)”– Anna 
Nachtnebel 
b “Tocolysis in preterm Labour” – Philipp Mad 
As the board members the members of the Scientific Advisory Group had a 
discussion (2-hours “hearing”) with the evaluators on their perception of 
LBI-HTA´s quality of research and scientific output. 
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1.4 Staff & Human Resources Development 
Besides the organisational development of an interdisciplinary research in-
stitute, professionalisation and specialisation of the team members are key 
issues. Becoming an interdisciplinary research institute involves the ex-
change of perspectives and methodologies, cooperation during projects, in-
ternal presentations and discussions and internal evaluations in order to en-
sure high quality work. 
Due to the rapid growth of LBI-HTA a reorganisation took place in 2009. 
Three departments were formed. The two new “head of departments” Dr. 
Ingrid Zechmeister (health economics) and Dr. Brigitte Piso (Public Health 
and health services research) attended a leadership training on “personnel 
training” (Business Circle, Wien. 03.-04/12/2009). 
The Ludwig Boltzmann Society initiates regular director meetings in order 
to increase both management capacities and identity building. Claudia Wild 
attended on 23-24/02/2009 the leadership training seminars „Re-
organisation of the workshop group, management, internal issues” (1st day) 
and „Leadership, conflict management, creatitvity“(2nd day) at the Vila Vita 
Hotel Pamhagen in the Burgenland. 
All researchers took part in the following methodology development co-
urses: 
b „Clinical Epidemiology“ (Part 1), LBI-HTA, Vienna (Lecturers: 
Philipp Radlberger, Stefan Mathis), 09/02/2009 
b „Clinical Epidemiology“ (Part 2), LBI-HTA, Vienna (Lecturers: 
Erwin Falkner, Kylie Thaler, Andrea Chapman), 10/02/2009 
b „Schlaganfall/Stroke“, LBI-HTA, Vienna (Lecturer: Peter 
Wipfler), 13/02/2009 
Several researchers attended the following courses: 
b Course „Introduction to HTA“, UMIT/Hall in Tirol, 25.-
28/02/2009 (Michael Gyimesi, Sabine Geiger-Gritsch) 
b Workshop „Systematische Übersichtsarbeiten in der Medizin- 
Grundkurs Evidenzbasierte Medizin“, Deutsches Cochrane Zen-
trum, Freiburg/Deutschland, 26.-28/03/2009 (Tim Johansson) 
b Young Gastein Brussels Study Visit der EU-Kommission (DG-
SANCO & DG-Research) und European Health Management 
Association, Brussels, 30/03.-01/04/2009 (Philipp Radlberger) 
b Workshop „Herausforderungen bei der systematischen Quali-
tätsbewertung von Interventionsstudien im Bereich Public 
Health“, Hannover/Germany, 05/06/2009 (Anna Nachtnebel) 
objectives: 
professionalisation, 
specialisation 
leadership training for 
director 
methodological training  
 
clinical epidemiology, 
EndNote 
specific training for 
some researchers: 
EBM, HTA 
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b Pre-conference workshop „ Information Searching for HTA – 
Globalisation, Localisation and Adaptation“, HTAi conference, 
6th Annual Meeting, Singapore, 21/06/2009 (Anna Nachtnebel)  
b Pre-conference workshop „Economic Evaluation for HTA“, 
HTAi conference, 6th Annual Meeting, Singapur, 06/2009 
(Philipp Radlberger) 
b „Medizinische Entscheidungen aus gesundheitsökonomischer 
Perspektive. Welchen Stellenwert hat in diesem Zusammenhang 
die Labordiagnostik für Mensch und Gesellschaft?“ 17. Abbot 
Medical Circle. Vienna, 25/09/2009 (Anna Nachtnebel) 
b Workshop „Health Technology Assessment”, Donau-University 
Krems, 05.-10/05/2009(Gerda Hinterreiter) 
b Short Course „Discrete Event Simulation for Economic Analy-
ses“, ISPOR 12th Annual European Congress, Paris, 24.-
27/10/2009 (Michael Gyimesi) 
b Short Course „Pharmacoeconomic Modeling – Advanced“, IS-
POR 12th Annual European Congress, Paris, 24.-27/10/2009 
(Michael Gyimesi) 
b “Using Utility Data in Cost-Effectiveness Models.” The Univer-
sity of Sheffield, Sheffield/UK, 08 – 09/ 11/2009 (Anna Nachtne-
bel) 
b Workshop „Die Qualitätsbewertung von Interventionsstudien - 
randomisierte und nicht-randomisierte Studien im Vergleich“ 
Institut für Epidemiologie, Sozialmedizin und Gesundheitssy-
stemforschung, Medizinische Hochschule Hannover, 05/06./2009 
(Brigitte Piso, Anna Nachtnebel) 
b Workshop Systematische Reviews „Publikation der Ergebnisse“, 
Donau-Universität Krems, Department für Evidenzbasierte Me-
dizin und Klinische Epidemiologie, Krems, 17/6/2009 (Brigitte 
Piso) 
b UCL Summer School “Social Determinants of Health”, Interna-
tional Institute for Society and Health, University of London, 
13.-17/07/2009 (Brigitte Piso) 
b Advanced training „Telestroke in practice“, 6th Stroke Network 
with Telemedicine in North Bavaria (STENO), Erlan-
gen/Germany, 12/10/2009 (Tim Johansson) 
b PR Briefing „Science Communication“, APA-OTScampus. ‘Haus 
der Industrie’, Vienna, 11/11/2009 (Gerda Hinterreiter) 
b Workshop „Communicating Science to the Media“, SciCom 09, 
Technical University Vienna, 17/11/2009 (Gerda Hinterreiter) 
b Pharmacoeconomics Workshop; IPPR conference series, Vienna, 
25.-27/11/2009 (Roman Winkler) 
b Training “The leading of team members”. Business Circle, Vi-
enna. 03.-04/12/2009 (Brigitte Piso) 
b Workshop “Instrument development and Evaluation of Patient 
Reported Outcomes Assessment”. HTA Assessment World 2009, 
08/12/2009 (Anna Nachtnebel) 
b Workshop “Pricing Medicines: An Integrated Framework for In-
coporating HTAs into P&R Strategy”. HTA Assessment World 
2009, 11/12/2009 (Anna Nachtnebel) 
health services research,  
 
 
economics,  
 
 
modelling,  
 
 
science communication,  
 
 
pharmacoeconomics 
 
PRO/ patient-reported-
outcomes 
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All LBI-HTA team members participated in the seminar workshop „Inspir-
ing instead of Presenting“ held by Justin Haiböck from „Menschen in 
Bewegung: 
b Group 1 (Philipp Radlberger, Sabine Geiger-Gritsch, Gerda Hin-
terreiter, Brigitte Piso): Donau-University Krems, 16.-17/04/2009  
b Group 2 (Smiljana Blagojevic, Stefan Mathis, Anna Nachtnebel, 
Tarquin Mittermayr, Roman Winkler, Michael Gyimesi, Tim Jo-
hansson): LBI-HTA, Vienna, 20.-21/04/2009 
In addition, Brigitte Piso, Anna Nachtnebel, Gerda Hinterreiter and Stefan 
Mathis participated in a TV and media training on 21/03/2009 at “IntoMe-
dia/ORF – Konrad Mitschka” in Vienna. After an introduction into media 
basics and the most important “do’s and don’t’s” regarding TV or radio in-
terviews, the seminar members were interviewed by Fritz Dittlbacher (mod-
erator) at a real media studio. The seminar participants had to prepare a 
particular topic and could train their skills in a “real world situation”.  
Stefan Mathis participated in an advanced rhetoric training (“Rhetoric II”) 
on 09.-10/01/2009 at the BFI Vienna.  
In October 2009, the Medical University Graz (Department for Social Medi-
cine) entiteled Claudia Wild to hold the position of a “Dozent” (“Habilita-
tion”). The title of the public presentation she gave was on "Resource alloca-
tion in health care“.  
As a part of his doctoral studies in National Economic Policy at the Vienna 
University of Economics and Business Administration, Philipp Radlberger 
attended the following classes: Research Seminar „Raising efficiency in SME 
health enterprises“ (held by Prof. Chini during winter term 2008/09), the 
Research Seminar „Political Economics“  (held by Prof. Österle during 
summer term 2009) as well as the Research Seminar „Specialisation in quali-
tative research methods“ (held by Prof. Brandtweiner during winter term 
2009/10).  
As part of his doctoral studies in Health Sciences Studies at the PMU/ 
Paracelsus Medical University in Salzburg, Tim Johansson attended in the 
summer term 2009 the courses „Anatomy“, „Physiology“, „Pathology“, 
„Clinical Studies and Evidence-Based Medicine“ as well as „Molecular 
Medicine“. 
Katharina Hintringer attended in the course of her master studies in Health 
Sciences at the University of Health Scienes, Medical Informatics and Tech-
nology (UMIT) in Hall in the Tyrol during winter term 2009/10 the follow-
ing courses: „Public Health/Health politics“, „Financial management“ and 
„Empirical Health Research“. 
presentation techniques 
– seminar &  
TV & media training   
university education: 
1 “habilitation” 
 
 
 
ongoing: 
 2 doctorates 
 
 
 
1 master 
  
The Institute – an Overview 
LBI-HTA | 2010 13 
As an interdisciplinary institute the organisation of work is guided by pro-
fessional – assigned topic-specific – project management. Again, the com-
pulsory weekly team meeting (Tuesdays at 2 p.m.) turned out to be essential 
and necessary for the team communication at the LBI-HTA. 
Director & Department High Tech in Hospitals: 
b Claudia Wild, Priv.Doz. Dr. phil. 
Research Background: Communication Science, Psychology, Political 
Science, Social Medicine 
Deputy Director & Department of Health Economics: 
b Ingrid Zechmeister, Dr. rer. soc. oec., MA 
Research Background: Health Economics 
Department of Public Health & Health Services Research: 
b Brigitte Piso, Dr. med., MPH 
Research Background: Medicine, Public Health  
Office-Assistant: 
b Smiljana Blagojevic, Dipl.-Ing. 
Assistant-to-the-director & Science Communications: 
b Gerda Hinterreiter, Mag. rer. soc. oec.  
Research Background: Medical Sociology, Communication  
Information Specialist: 
b  Tarquin Mittermayr, BA (Hons)  
Senior Researchers: 
b Philipp Mad, Dr. med. 
Research Background: Medicine 
b Rosemarie Felder-Puig, Mag. Dr. rer. nat., MSc (until 31/08/2009) 
Research Background: Psychology, Clinical research 
b Philipp Radlberger, Mag. rer. soc. oec.  
Research Background: Health Economics 
b Sabine Geiger-Gritsch, Mag. pharm., Dr. scient.med. (since 
01/05/2009 on maternity leave) 
Research Background: Pharmacy, Public Health 
b Stefan Mathis, Dr. med., Dipl.-Ing. 
Research Background: Medicine, Biomedical Informatics 
b Roman Winkler, Dr. phil, MSc  
Research Background: Communication Science 
b Tim Johansson, Mag. phil., MSc  
Research Background: Public Health 
b Michael Gyimesi, Dr. tech. Dipl.-Ing.  
Research Background: Modelling, Simulation  
b Anna Nachtnebel, Dr. med., MSc PH (since 01/01/2009)  
Research Background: Medicine, Public Health 
b Erwin Falkner (until 30/04/2009) 
Research Background: Biology 
 
project management 
team members  
a total of 16 persons =  
11 FTE  
 
and many cooperative 
research partners 
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Layout & Graphic Design: 
b Darko Blagojevic 
Trainees:  
b Katharina Hintringer, BA (01/10/2008 – 01/05/2009) 
Research Background: Social- and Health Management 
Junior Researchers: 
b Katharina Hintringer, BA (01/05/2009 – End of maternity leave Gei-
ger-Gritsch) 
Research Background: Social- and Health Management 
b Muna Abuzahra, BCS (since 01/06/2009) 
Research Background: Health Management 
b Martin Künzl (20/04/2009 – 16/11/2009) 
Research Background: Biology 
Literature Acquisition : 
b Johannes Setz 
b Laura Brückner 
b Mimoza Dulaj 
b Thomas Stumpner 
Student Assistants: 
b Johannes Flandorfer  
b Eva Salaberger 
Furthermore, there are also external experts working on several projects for 
the LBI-HTA. In 2009 those were  
b Anita Stergner, Mag. 
Research Background: Int.Economics and Business Administration 
b Bernhard Fleischner 
Research Background: Health Care Engineering 
b Christopher Adlbrecht, Dr. med. 
Research Background: Medicine 
b Ingrid Michl, Mag. 
Research Background: Pharmacy 
b Ines Schumacher, BA 
Research Background: Public Health 
b Irmgard Schiller-Frühwirth, Dr. med. 
Research Background: Medicine, Public Health 
b Marisa Warmuth, Dr. med., MIPH (FTE follows on 01/01/2010) 
Research Background: Medicine, Public Health 
b Martin Künzl 
Research Background: Biology  
b Nikolaus Patera, Mag. rer. soc. oec. 
Research Background: Economics 
many assistants 
external experts 
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Personnel, who left the LBI-HTA in 2009: 
Rosemarie Felder-Puig worked as a researcher at the LBI-HTA until 
30/08/2009. She was active in the field of psychology (30 hrs. /week); cur-
rently, she holds a position as a Senior Researcher at the new Ludwig 
Boltzmann Institute for Health Promotion Research (LBI-HPR). 
Erwin Falkner worked as a researcher at the LBI-HTA until 30/04/2009. At 
the LBI-HTA, he was active in the field of biology (10 hrs./week); currently 
he is involved in applied research projects.  
 
The Ludwig Boltzmann Institute for Health Technology Assessment, resp. 
its staff, is a member of the following international and national organisa-
tions: 
b HTAi (Health Technology Assessment international) 
b INAHTA (International Network of Health Technology Assess-
ment) 
b EUPHA (European Public Health Association) 
b DNEbM (German Network for Evidence-based Medicine) 
b HTA.de (Health Technology Assessment)  
b ÖGPH (Austrian Society for Public Health) 
b EuroScan (International Information Network on New and Emerg-
ing Health Technologies) 
b EUnetHTA (European network for Health Technology Assess-
ment) 
 
In 2005 Claudia Wild was appointed to the Supreme Health Council (advi-
sory committee of the Health Minister) for the first time. She is now in her 
second period. Additionally, Claudia Wild is a member of the Viennese 
Council of Bioethics and of the Scientific Advisory Committee of the EBM-
Working Group at the Austrian Federation of Social Insurances. Since au-
tumn 2008 Claudia Wild has also been a member of the Scientific Advisory 
Group of DAHTA@DIMDI as well as of the International Advisory Board 
of the “German Journal for Evidence and Quality in Healthcare” (ZEFQ). 
Brigitte Piso is a board member of the Austrian Society for Public Health 
(ÖGPH). 
Philipp Mad is a member of the European Pathway Association (EPA). 
Sabine Geiger-Gritsch is a member of the German Society of Medical In-
formatics, Biometrics and Epidemiology (GMDS) and of the International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR).  
Stefan Mathis is member of the Austrian Computer Society and the German 
Network for Health Services Research.  
Michael Gyimesi is since 09/2009 member of International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR).  
Tarquin Mittermayr is member of European Association for Health Infor-
mation and Libraries (EAHIL).  
institutional 
memberships  
individual  
memberships  
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1.5 Infrastructure 
The office of the LBI-HTA (279 m² in total) consists of seven separate rooms 
and a 70 m² library/seminar room. At the end of 2008, the institute was 
equipped with 16 personal computer workstations. For 2010 no further addi-
tions are planned. 
During the summer of 2009 the Institute’s library has undergone a major re-
organisation.  Project assistant Ms. Anita Stergner was engaged both in the 
stock-taking and re-cataloguing of the library’s books, applying the National 
Library of Medicine’s (NLM) method of classification. The books were sub-
sequently re-shelved according to NLM-Classification categories. Simulta-
neously a new internal loan scheme was introduced to improve both the 
traceability and retrieval of books. An increase in acquisition requests in 
2009 raised the number of books to 650. During the same period, the num-
ber of electronic journals rose to 16 titles, whilst - with currently eight titles - 
the number of subscriptions to print-journals remained constant.  
With Medline (via Ovid), Embase, Scopus and UpToDate, the LBI-HTA 
furthermore holds licences to four of the most important medical and scien-
tific databases. In addition to these, Ovid’s Transplant Library was tested 
during a trial period last autumn.    
Because the LBI-HTA intends to enable long-term and free access to its pub-
lications, strong emphasis has been placed on the (further) development of 
its document server (http://eprints.hta.lbg.ac.at) which provides extensive 
search options in English and German. In order to raise awareness of the In-
stitute’s research results internationally, summaries and other relevant in-
formation are regularly sent to the INAHTA office. Due to this co-operation, 
project reports and rapid assessments from the LBI-HTA have also been in-
corporated in the HTA-Database of the Centre for Reviews and Dissemina-
tion in York, and are accessible via http://www.crd.york.ac.uk/crdweb/. 
Tarquin Mittermayr is responsible for the institute's library and provides 
systematic literature searches for the LBI-HTA's scientific staff.  
1.6 Highlights of the Year 
On March 2nd 2009 the LBI-HTA hosted a scientific conference entitled 
'FairHealth: Equity and Resource Allocation of Medical Interventions' at 
the Urania in Vienna. Besides theoretical analyses, the conference focussed 
on national and international practical examples, interdisciplinary ap-
proaches to research and HTA-perspectives, all of which stressed different 
aspects of (in-)equity in health care. The conference was open to the public 
and admission was free. The significant interest in the conference and its 
subject-matter was reflected in the number of delegates (130) and their posi-
tive response. 
On May 7th and 8th 2009, three years after it was launched, the LBI-HTA 
was evaluated. The purpose of the evaluation was to decide, as was expected, 
whether the Institute would continue for a further four years; it was decided 
that it will do so. During the two day process the international evaluators 
(Prof. John GABBAY, University of Southampton; Prof. Andrew STEVENS, 
office space and 
equipment  
library 
international 
distribution 
„FairHealth“ conference 
evaluation of institute 
after 4 years 
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University of Birmingham, Public Health, Epidemiology & Biostatistics; 
Prof. Stefan N. WILLICH, Charité Berlin, Institute for social medicine, epi-
demiology and health economics and evaluation expert Dr. Simon SOM-
MER, Jacobs Foundation Zürich) interviewed not only the HTA-Team and 
its leaders, but also spoke to the LBI-HTA’s partners and Scientific Advisory 
Group about their experiences with the Institute. Both the Ludwig Boltz-
mann Society and the LBI-HTA team were delighted with the highly posi-
tive results of the evaluation, which clearly acknowledged the rapid devel-
opment of the Institute and the dedicated, high quality and valuable work 
done within it. 
A result of third-party-funded projects, such as those brought about by the 
demand for rapid policy advice, has been the growth of the Institute (16 em-
ployees and contributions from several external experts). In order to absorb 
this expansion without making sacrifices in the quality of its research, after 
its evaluation in May, the Institute underwent organisational reform. A re-
structuring workshop took place in Kritzendorf, near Vienna, on 02.06.2009. 
This led to the work and administration of the Institute being separated into 
three departments: 1. High tech in hospitals (Head of Department: Claudia 
Wild), 2. Public Health and health services research (Head of Department: 
Brigitte Piso) and 3. Health economics (Head of Department: Ingrid Zech-
meister). 
Following the review of Horizon Scanning programmes in 2006, a Horizon 
Scanning programme for oncology was developed and piloted. In 2009 this 
programme was tested in routine practice for the first time. The first Deci-
sion Support Documents for Horizon Scanning in oncology were published 
in the autumn of 2009. A group of oncology drugs was selected by scanning 
various data sources and websites. A group of interdisciplinary experts then 
decided for which of these drugs short and concise Assessments should be 
carried out and passed on to decision makers. (DSD Horizon Scanning in 
Oncology are available online at 
http://hta.lbg.ac.at/de/content.php?iMenuID=96). As the Horizon Scanning 
in oncology documents have been published (only) in English, they have 
aroused significant interest internationally, as well as in Austria. 
After the end of the EU EUnetHTA project (2006-2008), a group of 25 
European HTA institutions met in September 2008 in order to make strate-
gic and resource plans for the interim period in 2009. In 2009, the LBI-HTA 
was the only Austrian “founding partner” of the EUnetHTA network which, 
thanks to long-term EU funding, will become a “Joint Action” between 2010 
and 2012. In order to enable the EUnetHTA Joint Action partner organisa-
tions to reduce unnecessary overlaps and duplication in EU-wide HTA work, 
a web-based database of all planned and ongoing Assessments is being de-
veloped. Its development is being led by the LBI-HTA as part of Work 
package 7/ Stream B. Further projects in cooperation with other EUnetHTA 
partner organisations are planned and will be coordinated by the LBI-HTA 
from 2010. 
The evaluation of individual medical services (MEL) supports the decision 
of their inclusion in the benefit-catalogue, which was first carried out in 
2007/08, is now being regularly conducted. Completing this task in just a 
few weeks (mid-January to end of March) was not just a methodological 
challenge, but also an organisational one. The whole LBI-HTA team was in-
volved in this project, which has already led to a number of publications. 
Furthermore, cooperation with the LBI-HTA’s German counterpart, „NUB/ 
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New diagnosis and treatment procedures“, which is often simultaneously 
faced with similar or identical new medical techniques, is increasing. 
Transparent and comprehensible processing of data, assessments based on 
the GRADE tool, as well as (since January 2009) extraction tables written 
exclusively in English, all attract a great deal of international attention. As 
far as „globalisation of evidence, localisation of decision-making” is con-
cerned, these methods help to reduce overlap with HTA work around the 
EU. 
In 2009 the swine flu pandemic generated considerable media hype which 
reached its peak in the autumn. In order to help counter this mass hysteria 
boosted by the media, the LBI-HTA rapidly published an independent re-
port on the new strain of flu, including data and facts intended to aid policy 
decisions. In an an interview with the Institute’s director, Claudia Wild, on 
the Ӧ1  television  channel’s morning news bulletin  on 03/11/09,  the press 
finally  found a voice which warned against  scaremongering about the pan-
demic, and publicly argued for a rational view of the problem. The LBI-
HTA, represented by Claudia Wild, was featured in the media 35 times in 
relation to swine flu, in a combination of print, online, TV and radio contri-
butions. 
On the initiative of the ORAC publishing company, the Institute’s book 
“Zahlenspiele in der Medizin” (“Numbers games in medicine”) was written 
in the second half of 2009. The book deals with the often highly suggestive 
and therefore potentially misleading ways in which figures can be presented 
in the field of medicine. The 16 chapter book attempts to demonstrate these 
“numbers games”, using numerous examples which are notable for their im-
pact and/or timeliness. The aim of the book is to develop in its readers a cer-
tain awareness of these figures and statistics, and an understanding of how 
to interpret them. The book was compiled by 11 LBI-HTA employees and 3 
external experts, and edited by Claudia Wild and Brigitte Piso. It will be 
published on 08.03.2010. 
Nine members of the LBI-HTA team took part in the 11th Annual confer-
ence of the German Network for Evidence-Based Medicine, which took 
place in Berlin on 5th-7th July. In addition to their professional participa-
tion, participants used the opportunity for international networking. 
To mark the launch of the Ludwig Boltzmann Institute for Health Promo-
tion Research (LBI-HPR) an opening party was held at the Ottakringer 
brewery in Vienna on 19.03.09. The employees of the LBI-HTA were invited, 
and many attended the event. 
At the end of September 2009 (28.09-29.09) a two-day networking event in-
cluding a walking tour took place in Dorfgastein/Salzburg., in order to in-
tensify exchange and cooperation with  
b the Institute for Public Health, Medical Decision Making and 
HTA at the Private University for Health Sciences, Medical Infor-
matics and Technology/UMIT,  
b the Department for evidence-based medicine and clinical epidemi-
ology/ DUK and  
b for the first time the Federal Institute for Quality and Cost-
effectiveness in health care/BIQG  
prevention of overlaps 
in HTA work through 
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The aim of the networking event was for each institution to identify and de-
velop its profililing. 
The LBI-HTA Christmas party took place on 16.12.2009. It began with a 
tour of the “Bodycheck” exhibition at Vienna’s Technical Museum and was 
followed by a pleasant trip to the “Roter Elefant” restaurant. 
Finally, 3 employees of the LBI-HTA had children in 2009: Ingrid Zech-
meister (Paula: 22.12.2008), Sabine Geiger-Gritsch (Anna: 18.06.2009) und 
Stefan Mathis (Lorenz: 16.06.2009). These births were also celebrated ac-
cordingly. 
1.7 Research Programme 
The work program of the LBI-HTA consists of five programme lines, which 
will be briefly described. All projects will be explained in chapter 2 (re-
search), within the context of the different programme lines. 
Comprehensive assessments of health interventions & evidence-based 
health services research 
HTA can now look back on 20 years of methodological developments and in-
ternational harmonisation. „Traditional” assessments answer questions on 
new/innovative or established medical interventions such as  
b Is the intervention effective, does it work? 
b For whom, which subgroup of patients? 
b At what cost? 
b How does the intervention compare with alternatives? 
Unlike traditional HTA, evidence-based health services are still young, but 
are based on the same basic research principles: systematic literature search 
and analysis, transparent presentation of sources, process and results and in-
terdisciplinary perspectives. In contrast to the results from the critical ap-
praisal of medical interventions, the results from health services research are 
deeply anchored in the health systems concerned and cannot be as easily 
transferred into other systems. The research field of evidence-based plan-
ning follows the approach of distinguishing between demand and need and 
of critically questioning the actual utilisation of health services.  
For that reason, the LBI-HTA, as an HTA institute in a small country, is de-
voted to bringing international HTA into the national context and to further 
developing methods of evidence-based health services research. 
Scientific support of health policy and decision-maker networks 
Policy-relevant decisions are traditionally reached on the basis of a consen-
sus of high-ranking experts in boards and committees. This process of exclu-
sively expert-based (so-called eminence-based) decision-making is highly 
prone to bias, conflict of interests and doctrine. It is the aim of evidence-
based support to decision-making to collect and present recent research re-
sults and to provide a more rational and transparent input to the process of 
health policy decision-making, independent of influences from interest 
Christmas party 
children and births 
programme line  1 
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groups. The aim is to shape the process in the long term by systematically 
questioning marketed information and by asking for sound evidence. 
It is the task of the scientific support of health policy and decision-maker 
networks to react rapidly to demand and to present the evidence to decision-
makers in a transparent and readable format. 
Health Technology Assessment in hospitals 
The informal „HTA in hospitals” network consists of a group of about 20 
high-ranking decision-makers (medical directors and quality managers) 
from almost exclusively Austrian hospital cooperation. The network meets 
twice a year (June and October) in order to obtain informative HTA input 
into 4 key topics, to discuss them and to exchange ideas on regulation and 
reimbursement issues. 
The task of the LBI-HTA is to coordinate the meetings, to request and col-
lect current topics and to prepare the presentations. The format of the meet-
ings is for each topic to be presented from the HTA perspective and by an 
invited clinical expert, which subsequently leads into a structured discus-
sion.  
Scientific decision support of the Health Ministry 
It is the task of the LBI-HTA to provide - on request - scientific support to 
different committees of the Austrian Health Ministry (BMG, 
http://www.bmg.gv.at): 
b to support the Medical Advisory Group in the maintenance of the 
Austrian medical procedure classification (Austrian DRG Cata-
logue) with evidence analysis of new/innovative or established 
medical interventions. 
b to react to information enquiries in the Supreme Health Council 
(advisory committee of the Health Minister). 
Public understanding and research transfer 
Quite often - steered by early media coverage - the demand for 
new/innovative health care interventions emerges, even before market ap-
proval or reimbursement. „Public understanding” is both the transfer of 
knowledge about market forces and about methods for critically questioning 
the evidence presented on effectiveness and cost-effectiveness, appropriate-
ness, and methodological support for the differentiation between new and 
innovative interventions. „Public understanding” is meant to contribute to a 
better understanding of true effectiveness and, at the same time, to a democ-
ratic shaping of benefit packages. 
The intention of „public understanding and research transfer” is to build up 
- through presentations, seminars, monthly newsletter, a user-friendly web-
site and search support - a critical mass of patients, journalists, representa-
tives of the health administration, academia etc. that questions the informa-
tion presented and asks for sound evidence before decision making. 
 
programme line  3 
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HTA-implementation: Development and informing on effective policy in-
struments 
Evidence for the effectiveness and cost-effectiveness of numerous technolo-
gies and interventions can often only be presented after market approval and 
several years’ use under real clinical conditions. However, even then, ineffec-
tive technologies are widely spread and applied. Since it is ethically not jus-
tifiable to withhold true medical innovations from patients, and because 
pseudo-innovations absorb a lot of resources, taking new technologies under 
„surveillance” or „limited application” at specific medical centres is increas-
ingly frequently considered. Consequently, final decisions on reimburse-
ment are made only after patient-relevant outcome data become available. 
Methods for limited application and the assessment and appraisal of tech-
nologies and interventions after having obtained patient-relevant outcome 
data are still young. In this programme line, they will be further developed 
and applied. 
International cooperation / HTA Best Practice  
International cooperation and collaboration, particularly within the Euro-
pean Union, is becoming increasingly important in order to avoid redundan-
cies in the assessment of medical technologies prior to reimbursement or in-
clusion in public benefit catalogues. Drugs that have been approved by the 
European regulatory authority EMEA are being launched simultaneously in 
European markets. In addition, medical products and technologies are being 
launched nearly at the same time in European markets.    
The EU-project “EUnetHTA – European Network for Health Technology 
Assessments” is concerned with the development and implementation of 
structures and networks for transnational HTA-cooperation. This project 
was funded by the EU from 2006 to 2008 and was continued without public 
funding throughout 2009. From 2010 until 2012, in the form of a Joint Ac-
tion, it will be funded by the EU again. 
The LBI-HTA was co-initiator and has been a leading partner of EUnetHTA 
for years. The LBI-HTA manages work package 7 in close cooperation with 
the French HAS/Haute Authorité de Santé. Work package 7 is concerned 
with rapid exchange of information on the assessment of new technologies 
after their approval but prior to their introduction on the market. 
 
programme line  4 
programme line  5 
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2 Research 
2.1 Projects and Scientific Support of Decision-
making 
Economic aspects of clinically effective and efficient models of health 
services in alcohol addiction treatment 
Project leader: Philipp Radlberger  
Duration: 10/2007 – 04/2010 
Part 1: International models and approaches of outcome measurement 
(completed) 
Part 2: Selected models of integrated care and their evaluation (completed) 
Part 3: Comparison of services and costs in practical context: economic 
analysis of therapeutic institutions in Traun (GESPAG) ND Kalksburg (on-
going) 
Background: Increasingly, psychiatric and socio-medical therapeutic institu-
tions have to deal with the discussion and measurement of their outcomes. 
Given this fact, the project, which is structured in three parts, aims to pro-
duce a synthesis of published knowledge and its analysis in order to gain 
new knowledge for concrete evaluations of therapeutic institutions. Several 
highly heterogeneous approaches exist in the organisation of the services: 
easily accessible out-patient therapies, day-care, as well as in-patient ser-
vices. There is relatively little comparative evidence of clinical effectiveness 
of the different approaches, treatment results and costs.  
Aims and research objectives: To give an overview of the different treatment 
models, to analyse some models of integrated care, to reach conclusions 
about the evaluation of cost-effectiveness analysis of in- and out-patient 
therapies for people suffering from alcohol addiction, to transfer the main 
features of a model of integrated care services to the region of Salzburg and 
to carry out an economic evaluation of the existing and a potential inte-
grated care model.  
Method: Part 1: Systematic review, literature- and data analysis; Part 2: Ad-
ditional search of published and grey literature; hand search and internet re-
search for chosen models of good practice; direct contact and expert inter-
views; systematic organisation analysis of the three examples of integrated 
care according to their procedural design, gateway communication struc-
tures; analysis of grey literature and cost data available; formulation of qual-
ity indicators which could be benchmarks for other models of service of in-
tegrated care in alcohol addiction treatment;. Part 3: expert (group-) inter-
views, clinical and cost data description, cost-consequence analysis 
b description of actual structure of financing 
b definition of outcome parameters in clinical records 
b description of cost data 
b identification of successful treatment in clinical records 
b cost-consequence analysis 
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Results Part 1: Typologies of diagnosis and treatment planning are interna-
tionally incoherent. Some systematisations of health services are more ad-
vanced than others. There is a wide spectrum of alternative treatments in-
cluding medical interventions in short intervention withdrawal, psycho-
therapies, group-, family- and behavioural therapies as well as relapse pre-
vention measures and labour market reintegration facilities. According to 
the model of service supply, in-patient, out-patient or day care settings are 
chosen. Case management approaches implying individual carers helping 
with organising and coordinating flexible treatment structures stand in op-
position to treatment strategies where therapy plans are strictly fixed and 
scheduled immediately after diagnosis. Apart from evidence on clinical ef-
fectiveness, economic arguments can also influence the structures of health 
service supply. The fact that most countries are initiating screening pro-
grams is indicating that the economic importance of prevention is more and 
more recognised. General practitioners as gatekeepers can be considered key 
actors from an organisational point of view. 
Results Part 2: The comparison of three projects of integrated care in terms 
of combination of in- and out-patient treatments was done on the three lev-
els of structure, processes and results. The “addiction therapy in a linked 
system/EVS” centres the gateway management of institutional elements as a 
key quality indicator for the system by introducing a communication matrix. 
The evaluation of the Jellinek-model uses an adapted quality management 
tool for enterprises. Even though the UKATT as a big RCT with an eco-
nomic piggyback-design put the focus on clinical outcome parameters, au-
thors agree with the two other evaluations in considering the retention rate 
as highly relevant. 
Discussion: Overall there are many well evaluated single interventions, but 
only very few coordinated models of integrated alcohol therapy. Those who 
exist are mostly young, which explains a lack of evidence in the field of qual-
ity measurement. The analysis of a few regional pilot projects shows the high 
explanatory relevance of gateway management and retention rate for the 
overall quality of a treatment system in alcohol addiction. 
Publication (Part 1 & 2): HTA-Project report 10 - 
http://eprints.hta.lbg.ac.at/813/ 
Evidence supported health service planning 
Project leader: Stefan Mathis 
Duration: 10/2008 – 08/2009 
Background: Health services planning must consider aspects of demand (in-
cidence/prevalence and distribution of illness and health conditions) and 
aspects of supply (hospital services, physicians’ services, location and pay-
ment of medical equipment, drugs or medical devices, nursing services). 
Additionally, social aspects which have an impact on health and disease 
must be taken into account. Economic pressures to enhance the efficiency 
and quality and lower the costs of health care are reasons to scrutinise tradi-
tional methods of health services planning. While it is not the aim of this 
work (which is based on the methodological literature on health services 
planning) to make general recommendations for health services planning, 
we aim to identify ways of increasing scientific support and evidence based 
practice in the process of planning.  
programme line  1: 
assessments 
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Method: 1. Research questions were narrowed down by means of a scoping 
process. 2. A literature search was performed and (3.) publications contain-
ing detailed descriptions of applied planning methods (according to inclu-
sion/exclusion criteria) were selected. 4. The methods were described and 
(5.) steps in planning compared. 6. The essential steps in the planning guid-
ance analysed and the potential for using an evidence based approach to 
planning were discussed. 
Results: Based on the 34 public health care planning documents  identified, 
which included plans and planning methodologies, we selected 5 models for 
further analysis:  
b The English method of „Health Care Needs Assessment“ (HCNA)  
b The  Australian  „Community health needs assessment for health ser-
vice planning“ (CHNAP) 
b The American method of „Community Health Assessment and Action 
Planning“ (CHAAP),  
b The Canadian „Population needs-based health-care resource alloca-
tion and planning“ (PoNHRAP), as well as  
b The Austrian „Österreichische Strukturplan Gesundheit“ (ÖSG).  
By using the analytical framework of „Health Services Planning“ (Thomas, 
2003) – a strategic planning guide - core elements of the planning process 
can be compared. Obtaining information on the health of the population and 
the availability of services, as well as the evaluation of the benefit of the 
available health services, are important steps. The analysis also revealed that 
different planning methods focus on different areas (participation, prioriti-
sation, needs assessment, public health aspects, indicator choice, and service 
density)  
The comparative analysis also highlighted ways of intensifying the use of 
evidence and evidence based practice. The different planning methods use 
different types of evidence (knowledge of effects of implementation, analysis 
of policy, decision process analysis, knowledge of acceptability and values, 
knowledge of relative needs) and therefore require different methodological 
instruments.  
Discussion: Published and unpublished studies are required to develop the 
evidence base required in planning.  An objective consideration of the meth-
ods which can be used in health services planning is only possible if the 
planning steps are transparent. By using the core elements of planning iden-
tified in this review, one can analyse and – where required – optimise one’s 
own planning.   
Recommendations: We recommend evidence based planning. Health Tech-
nology Assessment/HTA may be applied in identifying objective need (by 
assessing net benefit) and may be of used in other aspects of planning 
Publication: HTA-Project report 21 - http://eprints.hta.lbg.ac.at/843 
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Classification of severity for neuro- and trauma rehab patients 
Project leader: Brigitte Piso 
Duration: 09/2008 – 01/2010 
Researcher (Part 1): Christoph Pammer, Muna Abuzahra, (Part 2): Muna 
Abuzahra, Brigitte Piso, (Part 3): Muna Abuzahra, Brigitte Piso.  
Part 1: Classification of severity for neuro- and trauma rehab patients. In-
struments used classifying stroke and trauma patients (completed) 
Part 2: International experiences in applying classification of severity for 
quality-assurance, performance-assessement and reimbursement (com-
pleted) 
Part 3: Applications of classification of severity for neuro- and trauma rehab 
patients in Austria (ongoing) 
Part 1: 
Background: The evidence, that the implementation of quality assurance 
systems in neurologic and trauma rehabilitation is able to improve patients´ 
functional health status is low. Indicators for outcome measurement should 
be assessed- not only for quality assurance reasons. Neurologic rehabilitation 
aims at improving the functional health status of patients as well as reinte-
grating patients in social participation. Therefore a variety of instruments 
for assessing functional health outcomes, activity and participation of pa-
tients have been developed and validated. The comprehensive and multi-
dimensional assessment of patients´ health status is the basis of allocation 
decisions, standardised planning in rehabilitation as well as coming up to 
the patients´ and the health care providers´ expectations. The selection of 
appropriate measuring instruments makes significant contributions to im-
proved patient care and its treatment outcomes. 
The first part of this project aimed at identifying instruments for classifying 
disease severity in patients with neurologic or trauma rehabilitation and as-
sessing them according to test quality criteria. As an example, chose two spe-
cific diagnostic groups (stroke and traumatic brain injury)  
Method: We identified 2527 publications by systematic literature search and 
hand search. 167 full text articles met our inclusion criteria and were in-
cluded in further analyses.  
Results: In stroke patients, specific instruments for classifying the severity of 
the disease show better test quality than generic instruments. We recom-
mend the National Institut of Health Stroke Scale (NIHSS), the Beck De-
pression Inventory (BDI), the Frenchay Activities Index (FAI), the Stroke 
Impact Scale (SIS) and the Stroke Specific Quality of Life Scale  (SSQOL) 
according to test quality criteria. In patients with traumatic brain injury 
specific instruments do not necessarily perform better than generic instru-
ments. We recommend the Disability Rating Scale (DRS) and the Commu-
nity Integration Questionnaire (CIQ). 
Conclusion: Instrument selection is not only dependant of test quality (and 
feasibility and acceptability issues), but also of the purpose the measure-
ments should serve in the system. Generic instruments can be used across 
different diseases, while additionally other criteria have to be assessed dis-
ease specific (modular composition of generic and disease specific instru-
ments). 
programme line  1: 
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For a choice of measurement instruments in neurological and trauma reha-
bilitation in Austria, aims of measurements have to be defined. It has to be 
clarified, whether and in which way measurements for quality assurance and 
outcome evaluation will be implemented and if it will be connected to reim-
bursement. 
Part 2: 
Background: Neurologic and traumatologic rehabilitation are highly com-
plex. The evaluation of quality and performance is important in order to 
meet the requirements of patients, care providers and funders of health care. 
Increased efficiency can be achieved by using outcome-oriented payment 
models.  Differentiation by severity of disease using generic (overall diagno-
sis) assessment instruments could be used in quality measurement and 
linked to reimbursement systems. 
Method: This report considers whether and which generic assessment in-
struments are used in quality and performance measurement, or in deter-
mining levels of reimbursement, in neuro and trauma rehabilitation. In par-
ticular, it explores international experiences with such instruments. A sys-
tematic literature review and a selective internet search were conducted in 
order to answer these questions. 
Results: In Germany and in Switzerland pilot studies of generic instruments 
for quality and performance measurement are being conducted. In Australia 
the AROC (Australasian Rehabilitation Outcome Centre) carries out quality 
measurement in rehabilitation almost nationwide, and uses the FIM (Func-
tional Independency Measure).  The application of generic instruments in 
outcome orientated payment systems has been tested in Germany using the 
FIM and the SINGER (Selbstständigkeitsindex für die neurologische und 
geriatrische Rehabilitation). In Switzerland, the LTR (leistungsorientiertes 
Tarifmodell, performance-oriented tariff model) is currently being tested. In 
Great Britain the RCS (Rehabilitation Complexity Scale), the NPDS 
(Northwick Park nursing Dependency Scale), and the NPTDA (Northwick 
Park Therapy Dependency Assessment) have been developed and are cur-
rently being piloted. In Australia the AN-SNAP-Classification (Australian 
National Sub-acute and Non-acute Patient Classification System), in which 
the differentiation of severity is based on the FIM, has been developed. In 
the USA the FIM has been in use for the differentiation of severity in the 
PPS (Prospective Payment System) since 2002. 
Most of the studies reviewed which discuss the use of generic instruments in 
reimbursement are from the USA.  For the most part, they evaluate the PPS. 
The costs of neuro and trauma rehabilitation are higher than the level of re-
imbursement designated by the PPS. Since the implementation of the PPS, 
the average length of stay has decreased and rate of discharges to home has 
increased. 
Conclusion: Generic Instruments can be used for various purposes. In Aus-
tria, pilot projects of the use of generic instruments for the measurement of 
quality and/or reimbursement, which take into consideration previous in-
ternational experiences and projects, are recommended. 
Publication (Part 1 & 2):  
HTA Project report 23a: http://eprints.hta.lbg.ac.at/866/ 
HTA Project report 23b http://eprints.hta.lbg.ac.at/867/ 
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Part 3: 
Following the two literature reviews, part 3 will empirically analyse the 
status quo of classification the severity for neuro- and trauma rehabilitation 
patients in Autria. To this effect several neuro- and trauma rehabilitation 
centres will be surveyed by using a questionnaire that will include at least 
the following questions:  
b Which instruments are used for classifying the severity for patients 
in neuro- and trauma rehabilitation centres in Austria? 
b Which purpose are they used for? 
b Are there already pilot projects excisting in classifying of severity 
for neuro- and trauma rehabilitation patients? 
 
Coverage with Evidence Development - Experiences from selected 
countries 
Project leader: Anna Nachtnebel 
Duration: 10/2008 – 01/2009  
Background: In order to allocate scarce resources effectively, reimbursement 
decisions for health technologies should be evidence-based. However, deci-
sion-makers are often confronted with the problem that study results are ei-
ther not applicable to clinical routine or that high quality data is not avail-
able at all. Possible consequences of decisions under uncertainty could be 
high opportunity costs in terms of wasting limited resources or increased 
risks for patients. 
Methods: This project was based on information available in the public do-
main, primarily on the websites of the included institutions CMS, MSAC 
and NICE. Additional data was identified by conducting a literature search 
on PubMed Central and the HTA database. Remaining ambiguity was 
sought to be clarified by personal contact with experts. 
Results: The concept of Coverage with Evidence Development has already 
been employed in the USA, England and Australia. Despite differences in 
the terms used, the underlying principle is identical: Reimbursement of 
technologies is tied to the condition of further evidence generation. While 
providing an opportunity to influence study-designs and outcomes, decision-
makers should be enabled to obtain data specifically tailored to meet their 
needs without restricting access to promising technologies.  
Although the three countries investigated show substantial differences, simi-
larities exist in terms of the appliance of Coverage with Evidence Develop-
ment mostly for new or emerging technologies, the inclusion of evidence 
generated through a variety of study designs, as well as in the basic refusal of 
service providers to fund additional research. Further similarities include 
that several unresolved issues that seem to impact on the successful imple-
mentation of Coverage with Evidence Development. Some of the most im-
portant ones are questions concerning choice of the best study-design, iden-
tification of suitable technologies and of the best point in the life-cycle, con-
sequences for industry and patients and foremost, assurance of funding for 
additional studies.   
Conclusions: Although some differences can be found in the use of Coverage 
with Evidence Development in the USA, England and Australia, several 
common factors seem to determine the success of this decision-making tool. 
ongoing: 
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Suitable technologies and adequate study-designs should be identified in a 
clear and transparent process which includes all relevant stakeholders. If, 
additionally, appropriate funding mechanisms for further evidence genera-
tion are in place, Coverage with Evidence Development will prove a valuable 
means for reimbursement decisions.  
Publikation: HTA-Project report 24 - http://eprints.hta.lbg.ac.at/818/ 
 
Evaluations of child and adolescent psychiatry 
Project leaders: Roman Winkler (overall project, clinical evaluations of pro-
ject part 1 and applied evaluation research of project part 2),  
Philipp Radlberger (economic evaluation of project part 1),  
Ingrid Zechmeister (economic evaluation of project part 2).  
Part 1: Clinical and economic evaluations of child and adolescent psychiatry 
(completed).  
Duration: 10/2008 – 11/2009  
Part 2: Evaluation study at the University Department of Child and Adoles-
cent Psychiatry (Christian-Doppler-Klinik) in Salzburg (ongoing).  
Duration: 01/2010 – 12/2011 
Background: The treatment of mentally disordered children and adolescents 
largely uses extensive therapy concepts including medical, psychotherapeu-
tic and socio-pedagogical interventions, which are adjusted to patients’ indi-
vidual needs. However, in the context of therapeutic evaluations and quality 
assurance, there is a lack of evidence regarding therapeutic outcomes (such 
as clinical improvements, quality of life) and satisfaction rates of patients 
and their relatives concerning therapy care. Additionally, there is a need for 
socio-economic longterm outcomes assessing parameters such as school suc-
cess or working ability of mentally disordered children and adolescents. Re-
search also needs to focus on economic evaluations, which relate therapy 
outcomes to resource management. In Austria, applied evaluation research is 
still at the beginning. Hence, this co-operation shall inter alia contribute to 
improve the Austrian data basis on quality evaluations.  
Aims and research questions: The first project part pursued the goal to pro-
vide a systematic literature review regarding evaluation methods, to identify 
applied evaluation instruments and to analyse systematically therapy out-
comes such as clinical symtomatology, health-related life quality, patients’ 
satisfaction rates, socio-economic longterm outcomes and the cost effective-
ness of treatments. The overall aim was to identify adequate benchmarks for 
the Austrian context. Hence, project part 1 was based on the following re-
search questions: 
1. Which evaluation indicators and which methods and instruments 
have been used to evaluate treatment programmes for mentally dis-
ordered children and adolescents within the international context? 
2. Which therapy outcomes have been identified so far and which 
ones can be identified as benchmarks for the Austrian context? 
Which socio-economic longterm outcomes have been empirically 
analysed? (HTA project report number 27). 
3. Which costs, cost-effectiveness ratios and cost-benefit analyses have 
been documented in economic evaluations? (HTA project report 
number 28).   
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On the basis of these “theoretical reflections” on clinical and economic 
evaluation studies, further research activities will take place in co-operation 
with the University Department of Child and Adolescent Psychiatry at the 
Christian-Doppler-Clinic (Salzburg) from March 2010 onwards. This forth-
coming project part 2 pursues the aim to make use of those therapy out-
comes that turned out to be adequate and useful (according to the systematic 
reviews) in order to evaluate treatment programmes in Salzburg. The follow-
ing research questions will guide the research in project part 2:  
b Which clinically relevant changes and developments show children 
and adolescents who make use of the treatment programmes offered 
by the University Department of Child and Adolescent Psychiatry 
at the Christian-Doppler-Clinic (Salzburg)? 
b Which resources have been used before and during the hospital 
stay? How to understand the relation between treatment needs, 
costs and therapy outcomes?  
Methods project part 1: Systematic literature search of studies/reports in 
medical portals (Ovid Medline, Embase, CRD databases, PsycINFO, 
EconLit, ISI Web of Science), period 1985-2009; hand search; analysis; sys-
tematic literature review. 
Methods project part 2: Primary data surveys at the University Department 
of Child and Adolescent Psychiatry at the Christian-Doppler-Clinic (Salz-
burg); Quantitative (e.g. “MARSYS” questionnaires) and qualitative (inter-
views with patients, parents) instruments of Social Sciences Research.  
Project part 1 – Clinical findings: The therapeutic outcome, treatment satis-
faction and the health-related quality of life of the patients turned out to be 
the primary evaluation dimensions in the course of the systematic review. 
Evaluation indicators have been developed for the purpose of defining these 
dimensions. In this context, the clinical symptomatology was identified as a 
core indicator for medical, psychotherapeutic and psycho-social treatment 
programmes. The quality of the treatment process as well as the “communi-
cation culture” among the involved actors, were proposed as adequate 
evaluation aspects. This also linked to health-related quality of life issues fo-
cusing even more strongly on the assessement of patient’s own human re-
sources. In most cases, standardised empirical instruments were used to 
measure the evaluation indicators. The “MARSYS” system was of particular 
interest because of its comprehensive view of aspects relevant to be consid-
ered when treating mentally disordered children and adolescents. Regarding 
the study results, study authors of the selected publications widely report 
about significant improvements in terms of the clinical symptoms. Concern-
ing the “success factors” related to improved clinical pictures, the building 
of “sustainable relationships” during the course of treatment appears to be 
core for the initiation of “successful” treatments.  
Project part 1 - Economic findings: Over a period of 25 years, one systematic 
review and 25 single evaluations could be identified. Some indications, e.g. 
ADHD, are better examined than others. Regarding different interventions, 
there is disequilibrium in favour of family therapy interventions. Most of the 
evaluations are cost-effectiveness studies. Cost-effectiveness results of the in-
terventions assessed are low, compared to interventions evaluated in somatic 
medicine. Most of the studies identified are inadequately transparent, espe-
cially with regards to information on cost data collection and modelling. The 
transferability of the evidence is limited because of context-specific interven-
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tions. As to the collection of cost-data, most studies are taking a public pay-
ers or insurances perspective. Besides there are instruments, such as the 
‘Client Service Receipt Inventory’ which is not only covering expenses oc-
curring inside the public health system, but also other public or private 
costs. 
Publications:  
HTA-Project report 27: Evaluations of child and adolescent psychiatry. The-
ory and practice about measurement dimensions, indicators and instruments 
(Roman Winkler) - http://eprints.hta.lbg.ac.at/846 
HTA-Project report 28: Child and adolescent psychiatry part 2: A systematic 
review of health economic evaluations (Philipp Radlberger) - 
http://eprints.hta.lbg.ac.at/862 
 
Tocolysis in preterm labour - A systematic review of evidence-based 
guidelines, effectiveness and health economic evaluations 
Project leader: Philipp Mad 
Duration: 10/2008 – 05/2009 
Background: Premature birth before the end of the 37th week of gestation is 
associated with an increased risk of morbidity and mortality in newborns. 
The most frequent causes of early labour are infections, diseases of the 
uterus and the placenta, as well as fetal causes such as malformation. Using 
drugs to suppress labour (tocolysis) does not prevent the causes of imminent 
premature birth; in most cases the birth can merely be temporarily delayed. 
In Austria, the drugs used in tocolysis are the betamimetic Hexoprenalin, a 
low cost drug which often leads to cardiovascular side effects, and the oxyto-
cin receptor blocker Atosiban, which has fewer side effects but is more 
costly.  
Aims: The aims of the systematic review were to summarise (1) existing evi-
dence-based guidelines for the treatment of imminent premature birth, (2) 
existing studies on the effectiveness and safety of tocolysis and, (3) health 
economic evaluations of the tocolysis drugs currently authorised in Austria.  
Methods: Separate literature searches were carried out to answer each of the 
research questions. The 456 references identified were independently re-
viewed by two people according to predefined in- and exclusion criteria. 14 
papers were selected for inclusion in the review. 
Results: Evidence-based guidelines for tocolysis make the following recom-
mendations: 
b Tocolysis is only indicated before the end of the 34th week of preg-
nancy. 
b In routine practice only one cycle of tocolysis should be carried out in 
a 48 hour period. Neither a repetition of the treatment nor mainte-
nance therapy is recommended. Using a combination of several toco-
lysis drugs is also not recommended. 
b When tocolysis is required, corticosteroids should be administered to 
help lung maturation, and, if necessary, the patient should be trans-
ferred to a neonatological centre. 
b Contraindications for tocolysis are increasing intrauterine infections, 
and fetuses that are unviable due to malformations. 
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b Accompanying measures such as strict bed rest, hydration or sedation 
are not recommended in routine practice.  
Betamimetics were effective in delaying birth by 2 to 7 days compared to 
placebo. However, they did not change neonatal mortality and morbidity. No 
significant differences in effectiveness and safety were found between the 
different betamimetics.  
Publication: HTA Project report 30 - http://eprints.hta.lbg.ac.at/825 
 
Outpatient cardiac rehabilitation - Part 2: Evaluation of outcome and 
effectiveness of outpatient cardiac rehabilitation 
Project leaders: Michael Gyimesi, Brigitte Piso 
Duration: 10/2008 – Spring 2010 (Part 2) 
Background: Cardiac rehabilitation is an essential therapeutic step in ensur-
ing patient reintegration into work-, social- and family life following acute 
cardiac incidents or cardiac surgical procedures. Phase I of the cardiac reha-
bilitation is conducted in inpatients in terms of early mobilisation after an 
acute incident. The phase II cardiac rehabilitation normally takes 4-6 weeks 
and in many countries this is performed on an outpatient basis. In Austria 
only a small number of cardiac patients participate in outpatient rehabilita-
tion programs. However, the outpatient cardiac rehabilitation is assumed to 
be as effective and safe as inpatient rehabilitation care and in addition is 
more cost-effective. Phase III is always conducted on an outpatient basis and 
should support the sustainability of the rehabilitation. 
Aims and research objectives: On the one hand, the objective of the first part 
of this report (HTA project report 15 – http://eprints.hta.lbg.ac.at/800/) was 
to identify indicators which are suitable for the formative and summative 
evaluation of outpatient cardiac rehabilitation, and on the other hand to ana-
lyse appropriate methods or instruments to measure the processes and re-
sults. The aim of the second part is a long-term effect evaluation of the phase 
III outpatient cardiac rehabilitation. Which sustainable effects does the ad-
ditional phase III rehabilitation have following former in- and outpatient 
cardiac rehabilitation (phase I+II), in contrast to no further outpatient af-
tercare? 
Method: Data evaluation for measuring long-term effects of already existing 
outpatient rehabilitation programs on the basis of the following data: sick 
leave, number of hospital visits, medication, early retirement, socioeconomic 
status. 
 
Telemedicine in Stroke Management 
Project leader: Tim Johansson  
Duration: 11/2008 – 08/2009 
Background: Stroke is the third largest cause of death after cardiovascular 
disease and cancer in industrial countries and a major factor in permanent 
disability. Acute stroke care requires rapid assessment, including patients 
‘medical history and accurate diagnostics: “time is brain”.  
Patients who receive organised stroke unit care are more likely to survive, 
return home and make a good recovery compared to patients treated with 
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conventional care in general medical wards. Systemic tissue plasminogen 
activator (tPA) delivered within 3 hours after the onset of stroke symptoms 
for acute ischemic stroke patients has been shown to reduce subsequent 
morbidity and mortality. tPA dissolves the obstructing blood clot restoring 
blood flow before major brain damage has occurred. Telemedicine in stroke 
care allows a direct specialist consultation with a patient, patient monitoring 
and medical education. The putative advantages of telemedicine are 
improvements in the quality of stroke care and increased use of tPA, which 
is associated with better health outcomes. 
Objective: the objective of this report is to assess the feasibility, 
acceptability, and treatment delivery reliability of telemedicine systems in 
acute stroke management. A secondary aim is to explore the feasibility and 
acceptability of telerehabilitation interventions in stroke management. 
Methods: A systematic literature search and evaluation of peer-reviewed 
literature was performed in Ovid Medline, Embase, DARE-NHSEED-HTA 
(INAHTA) and The Cochrane Library. The search was limited to the years 
1995-2008. 144 references remained after the removal of duplicates. A 
further 8 articles were identified through handsearching, yielding a total of 
152 references. 
Results: In total 26 studies were included in this systematic review. 19 
studies assessed telemedicine technologies in acute stroke care. 7 studies 
used telemedicine technologies in stroke rehabilitation settings. There was 
wide variety in study designs, including randomized controlled trials, 
controlled clinical trials, qualitative analysis, and observational studies. 
Most studies on acute stroke care included data on tPA. In some cases the 
time from patient’s admission in hospital to the start of thrombolysis, also 
called “door-to-needle time”, was documented. “Onset-to-needle time” and 
“onset to admission” were other indicators that were measured. Transfer rate 
after consultation was commonly reported. Patients treated with tPA via 
telemedicine were often transferred to a stroke center for continuing 
monitoring and surveillance. Long term follow up at 6, 12 and 30 months of 
telestroke services demonstrated better functional health outcomes 
including reduced dependency and mortality, compared with conventional 
care. Patients and health care providers reported high levels of satisfaction, 
although no study had the assessment of this outcome as its main objective. 
There was limited evidence regarding the impact on resource utilization and 
cost-effectiveness.  
7 telerehabilitation studies were identified in the literature. It appears that 
telerehabilitation interventions involving stroke patients and/or caregivers 
improve patient satisfaction and caregivers’ mental health.  
16 telestroke programs worldwide were identified, with more than half of 
them in North America. Programs had different objectives and approaches 
regarding staffing, technology, and catchment areas. A wide range of total 
numbers of consultations was identified in the literature when comparing 
the interventions. 
Conclusion: Although there is limited reliable evidence, observational 
studies indicated that telemedicine systems can be safe, feasible, and 
acceptable in acute stroke management. Telestroke interventions can bring 
therapeutic benefits, which are currently mainly available in specialized 
stroke centers. Telemedicine associations were associated with an increased 
delivery of systemic tPA, which improved patients’ health outcomes. 
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Economic studies on telemedicine interventions in stroke management are 
lacking. Some studies reported investment costs for technologies and 
education for health personnel and only one study reported cost-
effectiveness. Studies of higher methodological quality are needed to explore 
the potential cost-effectiveness of telemedicine technologies in stroke 
management. 
It is difficult to draw conclusions from the small sample of telerehabilitation 
studies included in this report. The few identified articles show promising 
results in terms of improving stroke patients’ and/or caregivers’ well-being. 
More research is necessary to determine the impact of telerehabilitation 
services. 
Several programs have been identified as being at the forefront of telestroke. 
The lack of standardized measuring and reporting of resources and health 
outcomes constrain comparisons between telestroke networks and the 
determination of best practices. More research is needed to accurately 
measure the clinical and economic impact of telemedicine technologies in 
stroke management to support policy makers in making informed decisions. 
Publication: HTA- Project report 29 - http://eprints.hta.lbg.ac.at/844 
 
Status quo mammography screening:  
evaluation results from organised programs 
Project leaders: Nikolaus Patera, Claudia Wild  
Duration: 08/2009 – 12/2009 
Background: Breast cancer diagnosed at an early stage tends to have a better 
prognosis. Moreover, breast cancer in earlier stages can often be treated less 
aggressively. This influences the patient’s quality of life positively. Through 
detecting breast cancer as early as possible, mammography screening aims to 
reduce mortality from breast cancer. 
Aim: Providing an overview of evaluation results from organised 
screeningprograms, this report informs quality management of new 
programs and supports benchmarking efforts. 
Method: Internet search for evaluation reports of organised screening 
programs in published in German or English. Evaluation results were 
extracted, analysed and compared. 
Results: Evaluation reports from six countries were identified. Those 
(Germany, Australia, Ireland, Italy, Canada, New Zealand, United 
Kingdom) are presented in detail. Other countries – e.g. The Netherlands or 
Sweden – 
could not be included since the evaluation reports were not accessible in 
German or English.  
b All programs are successful in detecting small invasive cancer.  
b Aimed for participation rates are not met by programs – except for 
Ireland and the United Kingdom. 
Program specific process results show considerable variation: 
b Recall rates influencing detection and false positives vary widely. 
b E.g. tumors in the UK are more often operated on without prior 
verification of diagnosis than in Germany. 
programme line  1: 
assessments 
Forschung 
LBI-HTA | 2010 35 
b Time to diagnosis of screening-mammography and waiting time for 
recall appointment differ. These are shorter e. g. in Germany than in 
New Zealand. 
b Information provided to invited women for the decision to take part 
in screening or not is not given independently of program 
institutions (funders, service providers, management). Program 
evaluation is only rarely conducted independently of program 
institutions. Both fields require action. 
Conclusion: As a public health measure mammography screening addresses 
healthy women. Hoped for benefits and possible harms have to be balanced 
based on available evidence to justify program funding from the public 
purse. Long standing screening programs provide more and more data for 
evaluation and research. Younger programs only start to establish data 
collection infrastructure. This data plays a key role in the evaluation of 
screening. 
Publikation: HTA-Project report 35 - http://eprints.hta.lbg.ac.at/863 
 
Artificial food colours and Hyperactivity 
Project leaders: Ines Schumacher, Claudia Wild 
Duration: 03/2009 – 11/2009 
Background: Hyperactivity describes an overactive, exaggerated, and uncon-
trolled behaviour in children. Permanent restlessness has negative effects on 
the social environment (parents, siblings, and friends) but furthermore on 
learning abilities in school or kindergarten. Hyperactivity is one part of the 
attention-deficit hyperactivity disorder (ADHD). Further symptoms of 
ADHD are inattention and impulsivity; these symptoms are the most com-
mon diagnosed psychiatric disorder in children. A numerous range of ad-
vanced diagnostic instruments and psychological assessments exist to get a 
reliable diagnosis of ADHD. 
An ultimate explanation of the specific reasons for ADHD is still missing. 
Several factors as diet, especially artificial food colours, are discussed to con-
tribute to hyperactive behaviour in children since the early 70´s and are still 
being discussed. Artificial food colours are part of food additives. The ad-
mission is regulated by the European Food Safety Authority (EFSA) since 
2002. Within the EU there are 40 different kinds of permitted dyes, most of 
them belonging to the chemically produced group called Azo-dye. These 
dyes are used to create the bright colours in sweets, lemonade and ice cream 
as well as cosmetics and drugs. Their effects on human health are verified by 
the EFSA – nevertheless these artificial food colours are under suspicion to 
promote hyperactive behaviour and allergy. The following report is focuses 
particular on children as the target group.  
Methods: The aim of this HTA is to find evidence whether there is a correla-
tion between Azo-dyes and hyperactivity in children. The search included all 
published systematic reviews and controlled trials. Two systematic reviews 
and eleven controlled trials could be identified, respectively. Two random-
ised control trials were focussed on a general population the others selected 
children who were already suspected as hyperactive. 
Results: The majority of the studies suggested a correlation between artifi-
cial food colours and increased hyperactivity in children. However, the de-
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sign and methods varied extremely between studies which complicates the 
comparison and drawn conclusions. The hypothesis of a correlation can nei-
ther be affirmed nor be abolished. 
Conclusion: Methodical problems like the inappropriateness of study de-
signs and applied methods need to be tackled. To achieve evidence for the 
impact of several Azo-dyes further research is needed. 
Publication: HTA-Project report 34 - http://eprints.hta.lbg.ac.at/848 
 
Acquisition processes of certain product groups in hospitals -  
orthopaedic and cardiac implants 
Project leaders: Bernhard Fleischner, Claudia Wild  
Duration: 03/2009 – 12/2009 
Background: Increasing cost pressure due to demographic change of society 
as well as new and innovative developments also affect Austrian hospitals. It 
is essential to utilize resources in a humane and economic efficiently way. 
Especially the product group ‘implants’ tends to challenge the supply man-
agement. The thesis presents a cross section of procurement of orthopaedic 
and cardiac implants in Austrian hospitals.  Furthermore, several aspects 
strongly connected to the overall concept of efficient supply management are 
surveyed. 
Methods: Used methods were a literature review on procurement of implants 
as well as guideline-based expert interviews. The interviewed experts were 
key players of selected organisations who were asked about organization, 
product choice and procurement strategies. 
Results: The results showed that procurement strategies in Austrian hospi-
tals are changing right now. However there is no common strategy which is 
implemented in all of the surveyed hospitals and networks.  Processes, 
grown over the years are only slowly being refined and so the optimization 
potential is not yet utilized. Already by EU-wide tendering, price reductions 
of about a double-digit percentage for implants seem to be achievable. 
Conclusion: This thesis could be a basis for further improvement of implant 
procurement. Subsequently, the several surveyed sub areas should be ana-
lyzed to identify optimization opportunities in procurement 
Publication: HTA Project report 38 – http://eprints.hta.lbg.ac.at/864 
 
Haemocomplettan® P and Fibrogammin® P 
in acquired hypofibrinogenemia 
Project leader: Marisa Warmuth 
Duration: 10/2009 – 01/2010 
Background: Haemocomplettan® P and Fibrogammin® P are being increas-
ingly used in the treatment of acquired hypofibrinogenemia to prevent or 
stop particularly perioperative bleeding within Austrian hospitals. Further-
more, decisions regarding the substitution of clotting factor concentrates are 
driven by measuring fibrinogen levels by thrombelastometry (ROTEM®) as 
a point-of-care device.  
Aims and research objectives: The aim of this systematic review is to inform 
decision makers about the current evidence regarding efficacy and safety of 
programme line  1: 
assessments 
programme line  1: 
assessments 
Forschung 
LBI-HTA | 2010 37 
fibrinogen- and FXIII- substitution with clotting factor concentrates in ac-
quired hypofibrinogenemia.  The objectives are firstly, to evaluate whether 
the administration of Haemocomplettan® P and/or Fibrogammin® P is su-
perior to the substitution of fresh frozen plasma/Octaplas® and/or cryopre-
cipitate in acquired hypofibrinogenemia; secondly, to explore the safety of 
Haemocomplettan® P and Fibrogammin® P; thirdly, to assess whether 
thrombelastometry (ROTEM®) is superior in providing information about 
transfusion requirements compared to standard laboratory hemostasis tests, 
such as the Clauss assay. 
Method: Systematic Review as outlined in the Internal Manual of the LBI-
HTA. 
PICO question: Efficacy and safety of Haemocomplettan® P and Fibro-
gammin® P in acquired hypofibrinogenemia in children and adults com-
pared to FFP and Octaplas® with special consideration of ROTEM® point-
of-care testing.  
Publication: HTA Project report 39 - http://eprints.hta.lbg.ac.at/870 
 
Evaluation of diagnostic technologies –  
Background, challenges, methods 
Project leader: Anna Nachtnebel 
Duration: 11/2009 – 08/2010 
Background: Diagnostic technologies are used to confirm or exclude the 
presence of disease or to classify disease. Ultimately, test results should im-
pact on diagnostic or therapeutic decisions, finally resulting in improved pa-
tient-relevant outcomes. For reasons that diagnostic tests can also be associ-
ated with adverse consequences, and uncritical use has led to a considerable 
impact on expenditures for health care, the identification of efficient and ef-
fective technologies is crucial. In order to ensure a reasonable allocation of 
resources, evidence-based principles, as for the evaluation of interventions, 
have to be applied.  In the HTA context, where diagnostics are assessed be-
yond their mere efficacy taking the most important consequences for pa-
tients and for health systems into account, unique methodological challenges 
occur. 
Aims and research objectives:  
1. To give an overview of specific methodological challenges associ-
ated with the evaluation of diagnostic technologies. 
2. To describe the methodologies used by selected institutions for the 
assessment of diagnostic technologies. 
3. Based on these findings, to develop a potential method for the 
evaluation of diagnostic technologies relevant to stakeholders. 
Research questions 
b Which parameters are used to describe diagnostic test accuracy (e.g. 
sensitivity, specificity, positive predictive value, pre-test probabil-
ity)? 
b On which levels can the effectiveness of diagnostic tests be evalu-
ated (e.g. test accuracy, patient relevant outcomes, implications for 
the health system)? 
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b Which methodological challenges are associated with the evidence-
based evaluation of the clinical effectiveness of a diagnostic test 
(appraising studies of diagnostic tests, linked evidence, missing ref-
erence tests)? 
b Which methods are used by selected institutions to evaluate diag-
nostic technologies; is there a common pattern which allows the 
drawing of a general valid approach relevant to decision-makers? 
Methods: Unsystematic hand-searches (manuals, guidelines, of selected in-
stitutions, Scopus, reference lists of relevant publications) and systematic 
literature searches of electronic databases (MEDLINE, EMBASE, HTA- da-
tabase) using Boolean operators, MESH terms (e.g. “diagnostics”, “evidence-
based medicine”) and free text search (e.g. “diagnostic test”, “methodology”, 
“evaluation”) to identify problems and methods used for the evaluation of 
diagnostic technologies. 
Categorization of the identified challenges and the description of relevant 
methodological approaches of the selected institutions, as well as the analy-
sis and synthesis of these approaches to determine a method relevant to 
health systems is the aim of the study.  
 
Evaluation of individual medical services 2009 before their inclusion 
into the hospital benefit catalogue 
Project leaders: Claudia Wild, Sabine Geiger-Gritsch 
Duration: 01/2009 – 04/2009 
Objective: Each year, the Austrian Ministry of Health, Family and Youth re-
ceives suggestions for numerous new medical interventions to get reim-
bursed. The aim of this project is to develop a standardized tool to evaluate 
the scientific evidence for these interventions. The assessments are based on 
systematic reviews for each intervention and a summary of the scientific evi-
dence according to the GRADE scheme. 
Methods: Systematic reviews and summary of evidence according GRADE 
 
Publications: 9 Decision Support Documents + 4 Updates (see below) 
b Chemo-nucleolysis and intradiscal electrotherapy. Systematic Re-
view. 
Decision Support Document 21a - http://eprints.hta.lbg.ac.at/828 
b Percutaneous nucleotomy and percutaneours laser disk decom-
pression. Systematic Review. 
Decision Support Document 21b - http://eprints.hta.lbg.ac.at/830 
b Injektion therapies and radiofrequency for the treatment of 
chronic back pain. Systematic Review. 
Decision Support Document 22 - http://eprints.hta.lbg.ac.at/831 
b Intraoperative radiotherapy for primary breast cancer. Systematic 
Review. 
Decision Support Document 23 - http://eprints.hta.lbg.ac.at/832 
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b Drug coated baloon catheter 
Decision Support Document 24 - http://eprints.hta.lbg.ac.at/833 
b Selective lgG Apheresis for ABO-incompatible kidney transplan-
tation 
Decision Support Document 25 - http://eprints.hta.lbg.ac.at/834 
b Image guided radiotherapy using cone-beam computed tomogra-
phy 
Decision Support Document 26 - http://eprints.hta.lbg.ac.at/835 
b Pumpless extracorporeal lung assist (PECLA) 
Decision Support Document 27 - http://eprints.hta.lbg.ac.at/836 
b Retroluminal transobturatoric reposition sling for the treatment 
of stress urinary incontinence in men 
Decision Support Document 30 - http://eprints.hta.lbg.ac.at/837 
 
4 MEL- Interventions/ Updates 2009: 
b Stent-grafting of the ascending aorta.  
DSD 14/ Update 2009: http://eprints.hta.lbg.ac.at/762/ 
b Cardiac contractility modulation for heart failure. Systematic review 
DSD 15/ Update 2009: http://eprints.hta.lbg.ac.at/769 
b Percutaneous aortic valve replacement. 
DSD 18/ Update 2009: http://eprints.hta.lbg.ac.at/766/ 
b Endobronchial valve implantation for emphysema.  
DSD 20/ Update 2009 (not published).  
International comparison of antenatal care in pregnant women  
Project leaders: Muna Abuzahra, Ingrid Zechmeister 
Duration: 05/2009 – 06/2009 
Background: Antenatal care has been offered by national programmes in 
Austria since the 1970s. Subsequently, the number of examinations has been 
increased continuously. However, medical progress requires constant adap-
tation of the programme.  
Aims and research objectives: The report wants to present those antenatal 
care examinations mainly, which aimes at an early detection of previous dis-
eases of the mother, and furthermore oppose them to examinations offered 
in national programmes of other countries. 
Results:  The international comparison of antenatal care has shown that it’s 
organised very heterogeneously in different countries. Type and number of 
examinations are only partly evidence based. One specific examination in 
Austria – the internal examination – is not offered elsewhere and such a pro-
gramme is also not addressed in evaluations of antenatal programmes. Hen-
ce, the additional benefit from this examination is unknown. There is a need 
for further resarch, especially concerning the effectiveness of examinations 
in antenatal care according to morbidity and mortality of mother and child. 
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Publication:  
Decision Support Document 33 - http://eprints.hta.lbg.ac.at/826/ 
 
New influenza (swine flu) – Data & facts for decision support 
Project leader: Claudia Wild 
Duration: 07/2009 – 08/2009 
Background: Decisions for extensive public health interventions must be 
made based on information without any influence by lobbies, mainly be-
cause those decisions are affecting many (also healthy) people and normally 
require a huge amount of public funding.  
Aims and research objectives: The current estival swine flu scare therefore 
prompted the LBI-HTA to help decision makers currently working on the 
national pandemic plan make objective decisions, by providing key data and 
facts about the „new influenza“.  
Results: Concerning the classification of the World Health Organization 
(WHO), the dimension of the „new influenza“ spread has been set at level 6 
(of 8). In contrast, the Center for Disease Control (CDC), who assesses the 
risk using the „Pandemic Severity Index (PSI) - which refers to lethality (the 
number of deaths in relation to the number of infected people) – rates the 
disease at level 2 (of 5). The WHO classification is a life cycle model, based 
on the global dispersion of the virus. According to the CDC’s calculations, 
the annual seasonal influenza causes up to 1 death per 1000 patients 
(0,10%), which equals a PSI of 1. In the United Kingdom (the country regis-
tering the most „new influenza“ cases in Europe at present) the lethality of 
the „new flu“ is about 0,14% (PSI 2 = 0,11-0,5%). Due to many harmless 
and unapparent courses of the „new influenza“, the real dimension of its ex-
pansion is at risk of being UNDERestimated and thus the actual mortality 
rate in danger of being OVERvalued. 
Publication:  
Decision Support Document 35 - http://eprints.hta.lbg.ac.at/845 
 
Autologous Chondrocyte Implantation 
Project leader: Martin Künzl 
Duration: 04/2009 – 12/2009 
Background: Since 1987, when (M)ACI was first mentioned, the technique 
has been used all over the world to treat osteochondral lesions in the knee. 
Nevertheless, the actual effectiveness of this relatively new treatment option 
is under question: clinical evidence based on controlled trials and long-term 
follow-up is still missing. For these reasons (M)ACI is being reimbursed in 
most countries only under research conditions. 
Methods: Systematic literature search in Medline via Ovid, Embase, Coch-
rane Library, NHS-CRD-HTA (INAHTA), ISI WEB of Science, WHO 
Health Evidence Network and Clinicaltrials.gov was complemented by a 
hand search. Inclusion criteria: Controlled clinical studies with more than 
20 patients and a follow-up period of at least one year. 
Results: The effectiveness analysis is based on 9 comparative clinical trials 
and 6 systematic reviews. Within the trials all together 566 patients were 
treated with mosaicplasty vs. ACI, microfracture vs. ACI, and ACI vs. ACI. 
programme line 2 
programme line 2 
Forschung 
LBI-HTA | 2010 41 
The results show consistency and confirm earlier (international) reviews. 
There is no evidence that ACI or MACI leads to better outcomes in the 
treatment of osteochondral lesions than any of the alternative treatments. 
ACI is not superior; at best equal, at much higher cost. The short term (1-2 
years) and mid-term (5 years) non-inferiority in highly selected active pa-
tients is proven. Long-term data are lacking. 
Publication: Decision Support Document 34- http://eprints.hta.lbg.ac.at/865 
 
Hyperthermia as an adjuvant in the therapy of designated tumor  
diseases 
Project leader: Stefan Mathis 
Duration: 12/2009 – 04/2010 
Background: Recent studies show advances for the clinical use of hyper-
thermia (heating target tissue by microwaves) a adjuvant therapy to conven-
tional tumortherapy. Additionally precision and quality control of the tech-
nology have improved over the past 5 years. Therfore we perform a system-
atic review on the clinical benefits of hyperthermia as a curative and as a 
palliative treatment option. 
Aims and objectives: Aim is to summarise the evidence profile of hyper-
thermia studies and to identify indications where hyperthermia has a bene-
ficial effect on patients. 
Method: Systematic review on patient relevant outcomes and recommenda-
tion for the use of hyperthermia. 
 
On request of the Upper Austrian health insurance and Chamber of Physi-
cains two rapid assessments/ Decision Support Documents on alternative 
medicine interventions were carried out. 
Project leader: Katharina Hintringer 
Duration: 03/2009 – 06/2009 
Background: In contrast to complementary medicine therapies like home-
opathy, so-called “humbug”-methods are currently not allowed to be pro-
vided by a statutory health insurance-authorised physician, regardless of the 
private demands of the patient. In line with doctor’s fee negotiations in 1998, 
the safekeeping of the quality of medicine as an allowance in kind was re-
arranged.  
Aims and research objectives: Therapies which are proved to be ineffective 
or even dangerous for patients’ health are not allowed to be provided. For 
that reason, decision makers need evidence based data on approx. 20 “hum-
bug”-methods in order to be able to ex- or include therapies from the cata-
logue of benefits. 
Two (of of 20 listed) “Humbug” methods were evaluated:  
b Bioresonance 
b Colon Hydrotherapy  
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Publications:  
b Decision Support Document 31: Bioresonance for allergiges, atopic 
dermatitis, non-organic gastrointestinal complaints, pain and rheumatic 
diseases - http://eprints.hta.lbg.ac.at/842/ 
b Decision Support Document 32: Colon Hydrotherapy for defecation 
disorders- http://eprints.hta.lbg.ac.at/827/ 
 
HTA in hospitals: Organisation and coordination of a network of deci-
sion-makers of Austrian hospitals and hospital-cooperations in the form 
of bi-annual meetings. 
Project leader: Claudia Wild 
HTA in hospitals, 16/06/2009, topics: 
b Acquisition and procurement of medical products and orthopaedic 
and cardiac impants: Processes, experiences, chances and chal-
lenges.  
Speakers:  
1. Univ.-Prof. DDr. Thomas Klestil: Geschäftsführer der Implantate-
kommission des LKH-Innsbruck 
2. DI Franz Laback, MBA: ehedem KAGes, jetzt NÖ-Holding, kaufm. 
Direktor LK Krems: 
3. Mag. pharm. Dr. Wolfgang Gerold, aHPh, Leiter der Stabsstelle 
Medizinökonomie und Pharmazie im KAV 
4. Mag. (FH) Barbara Pinter, Bundesbeschaffung 
 
b  Individual medical services (MEL) 2009: 7 short presentations 
1. Injektion therapies and radiofrequency for the treatment of chronic 
back pain (Anna Nachtnebel) 
2. Intraoperative radiotherapy for primary breast cancer (Claudia 
Wild) 
3. Drug coated balloon catheter (Philipp Radlberger) 
4. Selective IgG Apheresis for ABO-incompatible kidney transplanta-
tion (Stefan Mathis) 
5. Image guided radiotherapy using cone-beam computed tomography 
(Anna Nachtnebel) 
6. Pumpless extracorporeal lung assist/PECLA (Brigitte Piso) 
7. MEL-Updates 2008 (Claudia Wild) 
 
b Herceptin-Update (Claudia Wild) 
Methods: Presentations, Discussions 
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In line with programme line 3 - “Public understanding and research trans-
fer” - the following activities take place on a regular basis: public seminar-
series („decision support in health care”), semi-public training on methodol-
ogy, HTA newsletter and website. 
Project leader: Claudia Wild, Gerda Hinterreiter 
 
Equity and resource allocation of medical interventions 
Project leader: Roman Winkler  
Duration: 05/2008 – 2009 (conference on 02/03/2009, Urania Vienna) 
Background: The precarious situation of health care systems is evident. On 
the one hand, scarce budgets and high debts threaten the long-term financ-
ing of medical interventions for citizens. On the other hand, more and more 
cost-intensive medical innovations, which are to be made accessible to the 
public, appear on the market.  
Aims and research objectives: Apart from questions of use and efficiency of 
individual medical interventions, the FairHealth conference will deal with 
all those current problems and questions focusing on a fair distribution of 
medical performances. The need for such broad, public discussions primar-
ily results from the socio-political, individual and economic meaning of 
‘health’ as well as from recent debates concerning health care reforms. 
Method: In the light of this, the LBI-HTA has organised the FairHealth con-
ference on March 2 2009, in order to discuss issues of equity and resource al-
location of medical performances in a solidly financed health system. Be-
sides theoretical analyses, the main conference foci will cover national and 
international practical examples, interdisciplinary approaches to research 
and HTA-perspectives, which stress different aspects of (in-)equity in health 
care. The conference is open to the public with free admission.  
Lecturers: 
Dr. Christiane Druml (Österreichische Bioethikkommission beim Bundes-
kanzleramt) 
Dr. Claudia Wild (LBI-HTA 
Univ. Prof. Dr. Olaf von dem Knesebeck (Universitätsklinikum Hamburg 
Eppendorf) 
Univ. Prof. Dr. Friedrich Breyer (Universität Konstanz) 
Univ. Prof. DDr. Michaela Strasser (Universität Salzburg) 
Dr. Lilly Damm (Medizinische Universität Wien) 
Univ. Prof. Dr. Georg Marckmann, MPH (Universität Tübingen)  
The conference program is available online at: at: 
http://hta.lbg.ac.at/media/pdf/FairHealth_LBI_HTA_ENDPROGRAMM.pdf 
 
The seminar series “decision-support in health care" addresses the health 
administration, journalists, academia in health care and the interested gen-
eral public. Four to six presentations, often advanced training sessions - 
conducted by specialists - on methodological questions are offered, with free 
admission. Duration: two hours plus discussion. 
In 2009 four seminars were organized and attended by 20 to 30 persons. 
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QALY – Ökonomische und ethische Aspekte  
08/06/2009| 11:00-14:00 | LBI-HTA 
Lecturers: Prof. Dr. Uwe Siebert (UMIT)  
PD Dr. Dipl. Soz. Tanja Krones (Universitätsklinikum Marburg) 
Workshop „Causal Inference in Modeling “  
08.06.2009| 14:30-16:00 | LBI-HTA 
Lecturer: Prof. Dr. Uwe Siebert (UMIT) 
Workshop “Horizon Scanning in Oncology” 
12.02.2009 | 13:00-17:00 | LBI-HTA 
Lecturer: Dr. Sabine Geiger-Gritsch (LBI-HTA) 
Symposium and workshop “Qualitätssicherung und Ergebnismessung in 
der Rehabilitation: Erfahrungsberichte aus Deutschland und ausgewählte 
österreichische Pilotprojekte“ 
15.10.2009 | 11:00-16:30 | LBI-HTA 
Lecturers: Dr. Brigitte Piso, MPH (LBI-HTA) 
PD Dr. Dipl. Psych. Erik Farin (Universitätsklinikum Freiburg) 
Dr. Ute Polak (AOK Bundesverband Berlin) 
Dr. Gottfried Endel (HVB) 
 
The aim of a periodical, electronic-only HTA newsletter is to transfer the re-
sults of international assessments into a German-language, easily readable 
journalistic format: each month four articles on relevant technolo-
gies/interventions are selected. Often, but not always, topics which at least 
two different HTA institutions have worked on and published independently 
are chosen. An editorial article, often written by an invited expert, deals with 
horizontal topics such as methodological aspects or questions of health pol-
icy. The newsletter has been published 10 times per year since May 2006. 
Our electronic HTA newsletter is distributed to about 900 people in Austria 
and Germany has received positive feedback. In 2009 the download website 
of the HTA newsletter (http://hta.lbg.ac.at/de/newsletter.php?iMenuID=63) 
counted between 613 (July) and 1.670 (August) visits, with a total annual 
number of 13.907 visits. 
Figure 2.1-1: Download HTA newsletter 2008 & 2009 
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Project leader: Claudia Wild, Gerda Hinterreiter  
Duration: 10 x p. a. 
In 2009 mainly print media, but also radio- and tv-stations published a total 
of 50 articles/reports/press notices reporting on the LBI-HTA or its team 
members. Especially the swine flu pandemic generated considerable media 
hype, so in relation to swine flu the LBI-HTA, represented by Claudia Wild, 
was featured in the media 35 times (print, online, TV and radio contribu-
tions). 
Der Clou mit Tamiflu 
Date: 14/12/2009 
Medium: Der Standard 
Article 
 
Verschwörungstheorien: Der Schweine-Wahn im Internet 
Date: 19/11/2009 
Medium: Kurier 
Article 
 
H1N1-Virus hat eine soziale Komponente 
Date: 16/11/2009 
Medium: Der Standard 
Article 
 
Neue Grippe: Die Pandemie im Kopf 
Date: 15/11/2009 
Medium: Die Presse 
Article 
 
Strategien gegen die Grippe 
Date: 10/11/2009, 21:05 
Medium: ORF 2 / Report 
TV reportage & text 
 
Diskussion zur Schweinegrippe-Impfung 
Date: 10/11/2009, 18:05 
Medium: Radio Steiermark 
Radio & text 
 
Schweinegrippe: Echte Gefahr oder Hysterie? 
Date: 04/11/2009 
Medium: Ö1 Journal Panorama 
Radio & text  
 
Keine Grippe wie jede andere 
Date: 04/11/2009 
Medium: Die Presse 
Article 
 
Neue Grippe: Kinder stecken sich leichter an 
Date: 04/11/2009 
Medium: Kurier 
Article 
 
Kritik an Diskussion: Dasselbe wie jede andere Wintergrippe auch 
Date: 03/11/2009 
LBI-HTA in the media:  
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Medium: derStandard.at 
Article 
 
Expertin sieht keinen Grund zur Panik 
Datum: 03.11.2009 
Medium: news.orf.at 
Article 
 
Schweinegrippe wie normale Grippe? 
Date: 03/11/2009 
Medium: ORF Teletext 
Article 
 
Schweinegrippe - Expertin kritisiert überzogene Diskussion 
Date: 03/11/2009 
Medium: Ö1 Morgenjournal 
Radio & text 
 
Seuchen-Suche: Ist die Aufregung ein Coup der Pharmaindustrie? 
Date: 02/11/2009 
Medium: Profil 
Article 
 
Schwindel mit der Schweinegrippe: Ist die Aufregung ein Coup der Phar-
maindustrie? 
Date: 31/10/2009 
Medium: profil online 
Article 
 
Vernünftiger und kosteneffektiver Umgang mit der Influenza 
Date: 28/10/2009 
Medium: Medical Tribune 
Article 
 
Impfung gegen A(H1N1) startet - Kritische Betrachtung 
Date: 28/10/2009 
Medium: Medical Tribune 
Article 
 
Grippe: Viel Lärm um ein Virus 
Date: 10/2009 
Medium: Treffpunkt AKNÖ 
Article 
 
Der Impfkrampf 
Date: 10/2009 
Medium: Datum 
Article 
 
Milliarden-Erreger 
Date: 09/10/2009 
Medium: Format 
Article 
 
Willfährige Ärzte 
Date: 18/09/2009 
Medium: Medianet 
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Article 
 
Fatale Personalunion von Einkäufern und Nutzern 
Date: 09/09/2009 
Medium: Beschaffung Austria 
Article 
 
Neue Grippe: Was Tamiflu wirklich bringt 
Date: 09/09/2009 
Medium: Kurier 
Article 
 
Thema: Schweinegrippe - "Milde Grippe" in Österreich 
Date: 07/09/2009 
Medium: Der Standard 
Article 
 
Impfung: Die Wirkung sollte nicht überschätzt werden 
Date: 04/09/2009 
Medium: Kurier 
Article 
 
Nachrichten u.a. zur "Schweinegrippe" 
Date: 03/09/2009 
Medium: RTV Radio Arabella 
Radio 
 
Aktueller Bericht zur "Schweinegrippe" 
Date: 03/09/2009 
Medium: Der Standard Online 
Article 
 
Neue Grippe maßlos übertrieben? Studie kritisiert unsinnigen  
Aktionismus 
Date: 03/09/2009 
Medium: Die Presse 
Article 
 
Geld effizient einsetzen 
Date: 03/09/2009 
Medium: Die Presse 
Article 
 
Neue Grippe: Neue Studie gibt Entwarnung 
Date: 03/09/2009 
Medium: Die Presse 
Article 
 
Minister niest uns was vor 
Date: 02/09/2009 
Medium: Österreich/ Wien 
Article 
 
Schweineteuer 
Date: 31/08/2009 
Medium: trend 
Article 
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Erstellung einer evidenz-basierten Entscheidungshilfe zur HPV  
Impfung 
Date: 08/2009 
Medium: ÖGPH- Public Health Newsletter 3/2009 
Article 
 
Ein Virus als Geldspritze für die Pharmaindustrie 
Date: 21/08/2009 
Medium: Medianet Online 
Article 
 
Moderne Medizin: Wirkung, Nutzen und Kosten 
Date: 21/06/2009 
Medium: Der Standard 
Article 
 
Kongress: Eine e-mail als Feedback eines Kollegen aus der Steiermark 
Date: 05/2009 
Medium: Der Salzburger Arzt 5/09 
Article 
 
Schwein gehabt 
Date: 28/05/2009 
Medium: Pharma-Time 5/09 
Article 
 
"Gefahrenquelle Weiß". Ethische, philosophische und medizinische Über-
legungen über das Geschäft mit der Gesundheit. 
Date: 13/05/2009 
Medium: Ö1 - Salzburger Nachtstudio 
Radio 
 
Gute Geschäfte mit der Angst 
Date: 29/04/2009 
Medium: Der Standard 
article  
Medizin im Kepler-Salon 
Date: 11/04/2009 
Medium: OÖ Nachrichten 
Article 
 
Verteilungsgerechtigkeit von Gesundheitsleistungen 
Date: 05/03/2009 
Medium: Ärzte Woche 
article 
 
Grenzgang sanfter Druck zur Teilnahme an klinischen Studien 
Date: 05/03/2009 
Medium: Ärzte Woche 
Article 
 
Gesundheit gerecht verteilen 
Date: 05/03/2009 
Medium: Ärzte Woche 
Article 
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Fairhealth: Knapper werdende Ressourcen verlangen nach Strategien zur 
Erreichung von Verteilungsgerechtigkeit 
Date: 03/04/2009 
Medium: Ö1 - Dimensionen 
Radio 
 
Wie gerecht ist das Gesundheitswesen? 
Date: 02/03/2009 
Medium: science.orf.at 
Article 
 
Initative - Ein Schutzengel für die Heimfahrt 
Date: 20/02/2009 
Medium: Kurier 
Article 
 
Zwischen Vorsorge und Früherkennung differenzieren 
Date: 19/02/2009 
Medium: Ärzte Woche 
Article 
 
1 Jury & 300 Projekte 
Date: 02/02/2009 
Medium: NÖ Nachrichten 
Article 
 
Krebsimpfung: Expertenstreit ist noch lange nicht beendet 
Date: 25/01/2009 
Medium: Die Presse 
Article 
 
Das Geschäft mit der Grippe 
Date: 15/01/2009 
Medium: Die Presse 
Article 
 
The LBI-HTA press review 2009 is also available at: 
http://hta.lbg.ac.at/de/content.php?iMenuID=82 
Project leader/Presse: Gerda Hinterreiter  
 
The LBI-HTA website - http://hta.lbg.ac.at - contains updated announce-
ments or presentations of publications and reports, research projects, events, 
press reviews, team profiles and other current news concerning the LBI-
HTA.  
According to access statistics of the LBI-HTA’s website and its numerous 
pages (http://hta.lbg.ac.at), about 2 million hits (2.042.392) were registered 
in 2009. This corresponds to an increase of 642.828 hits compared to 2008. 
In 2009, the number of hits was highest in November (224.997), and lowest 
in December (135.960). 
Project leader/ Webmaster: Gerda Hinterreiter  
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Figure 2.1-2: Website hits 2008 & 2009 
 
Figure 2.1-3: Website visits 2009 
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Horizon scanning in oncology - Part II:  routine operation 
Project leader: Sabine Geiger-Gritsch, Anna Nachtnebel 
Duration: since 10/2008  
Background: The establishment of a Horizon Scanning System for antican-
cer drugs is an important tool to prepare Austrian hospitals for new/ emerg-
ing medicines. The first part of the project "Horizon Scanning in Oncology", 
which was carried out between July 2007 and May 2008, focused on the de-
velopment of a concept for a Horizon Scanning System in oncology and the 
testing of two important steps (i.e., "identification" and "prioritisation") in 
the context of a short pilot.  
In 2009 the routine operation started.  
Aims and research objectives: Based on the feasibility and pilot phase, the 
second part of the project aimed at the routine operation of the HSS.  An op-
timised final concept with various stakeholders (e.g. hospital administrators, 
clinical experts, drug commissions) was worked out, taking into considera-
tion the results of the feasibility study. In addition, the Horizon Scanning 
System was made standard practice at the LBI-HTA in order to regularly 
provide Austrian hospitals (hospital management and drug commissions) 
with information about new/ emerging anticancer drugs to support their fi-
nancial drug budget planning and rational decision making.  
Members of the interdisciplinary oncological expert team: 
Dr. Anna BUCSICS, Hauptverband der Österr. Sozialversicherungsträger, 
Abteilung Evidence Based Economic Healthcare, Wien;  
Dr. Michael POBER, KH St. Pölten, Hämato-Onkologie, NÖ Landesklini-
ken Holding;  
Dr. Johannes ANDEL, LKH Steyr, Onkologie und Public Health, GESPAG, 
OÖ;  
Mag. Andreas SEIRINGER, LKH Vöcklabruck, Leiter Krankenhausapothe-
ke – Pharmazeut, GESPAG, OÖ;  
Prim. Dr. Peter KRIPPL, LKH Fürstenfeld – Hämatologie und Onkologie, 
KAGES, Steiermark;  
Dr. Wolfgang WILLENBACHER, LKH Innsbruck Universitätsklinik, Hä-
mato-Onkologie, TILAK, Tirol;  
Mag. Sigrid KIENDLER, LKH Innsbruck – Stellv. Leiterin Krankenhaus-
apotheke – Pharmazeutin, TILAK, Tirol;  
Dr. Clemens LEITGEB, Wilhelminenspital - Onkologie und Hämatologie, 
KAV, Wien – Alle im Rahmen des Projektes „Horizon Scanning in Oncolo-
gy“  
Publications:  
Decision Support Documents Horizon Scanning in Oncology Nr.1-5 - 
http://hta.lbg.ac.at/de/content.php?iMenuID=96 
b Azacitidine (Vidaza®) for the treatment of myelodysplastic syn-
dromes  
b Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung 
Cancer  
b Everolimus (Afinitor®) for the treatment of advanced/metastatic 
kidney cancer 
b Rituximab (Rituxan®/MabThera®) for the first- and second-line 
treatment of chronic lymphocytic leukaemia  
programme line  4: 
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b Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after 
first remission in patients with follicular lymphoma 
 
Procedures in evaluation – kyphoplasty and vertebroplasty 
Project leader: Rosemarie Felder-Puig (until 31/08/2009), Brigitte Piso 
Duration:  2006 – 2010 
Background: Conservative treatment of vertebral compression fractures 
(VCF) in older patients includes bed rest and analgesics followed by mobili-
sation and eventually, the use of a bodice. Alternatively, two minimally inva-
sive procedures – percutaneous kyphoplasty (KP) and vertebroplasty (VP) – 
are available. Patients with osteoporotic VCF and chronic pain in particular 
may benefit from these techniques. VP, which is less costly than KP, induces 
quick pain relief. KP also leads to quick pain reduction. In addition, it is in-
tended to be safer and to restore vertebral height, as well as guaranteeing a 
lower risk of refracture. However, there is insufficient evidence about these 
benefits for patients. In particular, long-term results and cost-effectiveness 
data are scarce.  
Aims and research objectives: A study conducted at the Austrian AUVA hos-
pitals should be able to provide data about the effectiveness of KP and VP 
under real-life conditions. The study will be performed in cooperation with 
other clinics (University Clinics of Orthopaedics at Vienna and Graz, Ha-
nusch Hospital Vienna) and will collect data prospectively for a time inter-
val which has yet to be defined.  
Method: Empirical study, application study; co-ordination of participating 
institutions; production of study documents (protocol, CRF, patient consent 
form, application to Ethics Committee, registration); implementation, data 
entry and analysis; presentation of results and publication. 
Publication: Procedures in evaluation – kyphoplasty and vertebroplasty, In-
terim Report, July 2009 (not released to the public) 
 
Developing a decision aid on HPV-vaccination for young girls and 
women/mothers  
Project leader: Brigitte Piso  
Duration: 09/2008 – 06/2009 
Background: Epidemiological studies show that an infection with human 
papilloma virus (HPV) is an essential factor in the development of cervical 
carcinoma and its early stages. In addition to the effective cervical screening 
programs (PAP-smear), two vaccines against the two most common cancer-
causing strains of HPV have been licensed. Persuasive advertising by the 
companies does not provide reliable information about the disease, the vac-
cine or possible alternatives for young girls and women.  
Methods and result: A decision aid was developed on the basis of 
standardised, evidence-based, qualitative analysis on the evidence on deci-
sion aids and target groups, unsystematic web research, and also of a system-
atic literature review. The project consisted of three parts: first of all the con-
tent was expressed in plain text, suggestions for the graphical conversion 
were made and the readability and comprehensibility was tested in an Aus-
programme line  4 
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trian focus group. If new findings have been made public or complications 
have occurred, the content of the decision aid will be updated after one to 
two years. 
Publication: The decision aid on HPV-vaccinationis online available at:  
www.aok.de/hpv-entscheidungshilfe or www.hpv-entscheidungshilfe.de 
 
EUnetHTA Collaboration 2009 
Project leaders: Claudia Wild, Gerda Hinterreiter 
Durationt: 2006-2008; 2009; 2010-2012; 
Background:  In the course of termination of the EU-project EUnetHTA 
2006-2008 the partner organisations aimed at developing a strategic concept 
in order to ensure the continuity of EUnetHTA in the interim period of 
2009. Overall, a group of 25 partner organisations, so-called “founding part-
ners”, from 13 EU member states (+Norway and Switzerland) were actively 
working on the sustainability of this project. 
Aim and Methods: During 2009 the EUnetHTA “founding partner” were 
structuring and formulating a project proposal for a consectutive EU-
supported project “EUnetHTA Joint Action”. As in EUnetHTA 2006-2008, 
LBI-HTA is again co-leader of the workpackage 7. In 2010 to 2012 WP 7/ B 
will develop of a webbased database containing all ongoing and planned as-
sessements of the EUnetHTA Joint Action partner organisations in order to 
avoid redundancies in the HTA-production across the EU. 
Publications: Available at EUnetHTA website – http://www.eunethta.eu 
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2.2 Publications  
Pammer, Ch., Wild, C. (2009): Schweregraddifferenzierung in der Neuro- 
und Traumarehabilitation. Messinstrumente bei Schlaganfall und Schädel-
Hirn-Trauma. HTA-Projektbericht 23a.  
Abuzahra, M., Piso, B. (2009): Schweregraddifferenzierung in der neurologi-
schen und Trauma-Rehabilitation. Internationale Erfahrungen zur Quali-
täts-, Performancemessung und Vergütung. HTA-Projektbericht 23b. 
Gyimesi M, Tüchler H, Piso. B. (2009): Ambulante Kardiologische Rehabili-
tation Teil III. Retrospektive Kohortenstudie mit/ ohne Phase III Rehabili-
tation. 1. Teilbericht des HTA-Projektberichts 2010  (unreleased). 
Johansson, T., Wild, C. (2009): Telemedicine in Stroke Management- sys-
tematic review. HTA- Projektbericht 29. 
Mad, P., Geiger-Gritsch, S., Mittermayr, T., Wild, C. (2009): 
Medikamentöse Wehenhemmung bei drohender Frühgeburt. Systemati-
scher Review zu Leitlinien, Wirksamkeit und Gesundheitsökonomischen 
Evaluationen der Tokolyse. HTA-Projektbericht 30. 
Mathis S., Wild C., Piso B., Piribauer F. (2009): Evidenzgestützte Versor-
gungsplanung. HTA Projektbericht 21. 
Nachtnebel, A. (2009): Bedingte Erstattung - Erfahrungen aus ausgewählten 
Ländern. HTA-Projektbericht 24. 
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Mad, P. (2009): Tocolysis in preterm labour. A Systematic Review. HTA-
Boardmeeting. LBI-HTA, Vienna, 08/05/2009 
Mad, P. (2009): Vorstellung der Ergebnisse des AutorInnenarbeitskreises. 
LBI-HTA. Vienna, 24/11/2009 
Mathis, S. (2009): Zufall. Das Spiel des Zufalls und dessen Rolle für Studi-
energebnisse. LBI-HTA, Vienna, 03/02/2009 
Mathis, S. (2009): Evidence based Health Services Planning. Presentation of 
project results. LBI-HTA, Vienna, 22/09/2009 
Mathis, S. (2009): QUORUM becomes PRISMA. LBI-HTA, Vienna, 
13/10/2009 
Mathis, S. (2009): Software zum HTA-Management. LBI-HTA, Vienna, 
03/11/2009 
Mittermayr, T. (2009): The institute’s library. LBI-HTA, Vienna, 27/10/2009 
Nachtnebel, A. (2009): Health Technology Assessments at Ludwig Boltz-
mann Institute. Wissenschaftlicher Beirat des LBI-HTA. Vienna, 08/05/2009 
Nachtnebel, A. (2009): Bildgesteuerte Strahlentherapie mittels Cone-Beam 
CT. HTA in Krankenanstalten. Vienna, 16/06/2009 
Nachtnebel, A. (2009): Injektionstherapien und Radiofrequenztherapien bei 
chronischen Rückenschmerzen. HTA in Krankenanstalten. LBI-HTA, 
Vienna, 16/06/2009 
Nachtnebel, A. (2009): MELs and Grade. LBI-HTA, Vienna, 17/11/2009 
Piso, B. (2009): Development of an evidence-based decision-aid on HPV vac-
cination. Wissenschaftlicher Beirat des LBI-HTA, Vienna, 07/05/2009  
LBI-HTA intern lessons: 
21 intern workshops 
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Piso, B., Mathis, S., Mittermayr, T., Geiger-Gritsch, S. (2009): Pumpless ex-
tracorporeal lung assist (PECLA): Systematischer Review. HTA in Kran-
kenanstalten. LBI-HTA; Vienna, 16/06/2009 
Piso, B., Geiger-Gritsch, S. (2009): Stentgraftimplantation bei Erkrankungen 
der Aorta ascendens. Update 2009. HTA in Krankenanstalten. LBI-HTA; 
Vienna, 16/06/2009 
Piso, B. (2009): Publikation systematischer Reviews. LBI-HTA, Vienna, 
28/07/2009 
Piso, B. (2009): Social determinants of health. LBI-HTA, Vienna, 
22/12/2009 
Radlberger, P. (2009): Child psychiatry – economic evaluations. LBI-HTA, 
Vienna, 10/11/2009 
Wild, C. (2009): EUnetHTA, LBI-HTA, Vienna, 08/09/2009 
Winkler, R. (2009): Child psychiatry. LBI-HTA, Vienna, 13/10/2009 
 
Gyimesi M., Piso B.: Versorgungsplanung der kardiologischen Rehabilitati-
on unter Berücksichtigung von Sekundärdaten des österreichischen Ge-
sundheitssystems. 11. Jahrestagung des Deutschen Netzwerks Evidenzba-
sierte Medizin, „EbM - ein Gewinn für die Arzt-Patient-Beziehung?“ Salz-
burg, 25.-27/02/2010, as lecture accepted 
Johansson, T.: Akutes Schlaganfallmanagement mittels Telemedizin: eine 
systematische Übersicht. 11. Jahrestagung des Deutschen Netzwerks Evi-
denzbasierte Medizin, „EbM - ein Gewinn für die Arzt-Patient-Beziehung?“ 
Salzburg, 25.-27/02/2010, submitted 
Mathis, S.: Evidenzbasierung in der Versorgungsplanung, 11. Jahrestagung 
des Deutschen Netzwerks Evidenzbasierte Medizin, „EbM - ein Gewinn für 
die Arzt-Patient-Beziehung?“ Salzburg, 25-27/02/2010, as lecture accepted  
Geiger-Gritsch, S., Nachtnebel, A., Hintringer, K.: Horizon Scanning in der 
Onkologie – Konzeptentwicklung und Implementierung eines Früherken-
nungssystems für Krebsmedikamente in Österreich, 11. Jahrestagung des 
Deutschen Netzwerks Evidenzbasierte Medizin, „EbM - ein Gewinn für die 
Arzt-Patient-Beziehung?“ Salzburg, 25-27/02/2010, as lecture accepted 
Piso, B.: Outcomemessung in der Regelversorgung- Herausforderungen und 
Potenziale, eingereicht und als Poster angenommen für die 11. Jahrestagung 
des Deutschen Netzwerks Evidenzbasierte Medizin, „EbM - ein Gewinn für 
die Arzt-Patient-Beziehung?“ Salzburg, 25-27/02/2010, submitted 
Piso, B.: Health Technology Assessment based outcome research in routine 
care – challenges and opportunities, Health Services Research Working Con-
ference, The Hague, 08.-09/04/2010, submitted 
Radlberger, P.: Kinder- und Jugendpsychiatrie – Gesundheitsökonomische 
Evaluation und Möglichkeiten der Kostenaschätzung. 27. Jahrestagung der 
Österr. Gesellschaft für Kinder- und Jugendpsychiatrie, Klagenfurt, 25-
27/02/2010, submitted 
Radlberger, P.: Kinder- und Jugendpsychiatrie – Gesundheitsökonomische 
Bewertung. 11. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Me-
dizin, „EbM - ein Gewinn für die Arzt-Patient-Beziehung?“ Salzburg, 25.-
27/02/2010, as lecture accepted 
submitted and accepted 
lectures and 
contributions at 
conferences: 
13 already accepted  
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Radlberger, P., Zechmeister I., Wild. C.: Economic aspects of health ser-
vices in alcohol addiction treatment- Health Services Research Working 
Conference, The Hague, 08-09/04/2010, submitted 
Winkler, R.: Multimodales Evaluierungsdesign an der Salzburg Universi-
tätsklinik für Kinder- und Jugendpsychiatrie. 27. Jahrestagung der Österr. 
Gesellschaft für Kinder- und Jugendpsychiatrie, Klagenfurt, 25-27/02/2010, 
submitted 
Winkler, R.: Evaluierungen in der Kinder- und Jugendpsychiatrie. Theorie 
und Praxisbeispiele zur Qualitätssicherung. 11. Jahrestagung des Deutschen 
Netzwerks Evidenzbasierte Medizin, „EbM - ein Gewinn für die Arzt-
Patient-Beziehung?“ Salzburg, 25-27/02/2010, submitted 
Winkler, R.: Evaluation within the field of child and adolescent psychiatry, 
Health Services Research Working Conference, The Hague, 08-09/04//2010, 
submitted 
Winkler, R.: Fehl- und Unterversorgungen in der Kinder- und Jugendpsych-
iatrie. Tagung "Ungleich 2010", OÖGKK, Linz, 10/06/2009, submitted 
 
Felder-Puig, R. (2009): Optimierung der gesundheitlichen Versorgung von 
RückenschmerzpatientInnen in Österreich. 10. Jahrestagung des Deutschen 
Netzwerks Evidenzbasierte Medizin, Evidenz und Entscheidung: System un-
ter Druck. Berlin/ Germany, 05-07/03/2009 
Mathis, S. (2009): “Characterising registries for reviewing purposes: Three 
perspectives”, 10. Jahrestagung des Deutschen Netzwerks Evidenzbasierte 
Medizin, Evidenz und Entscheidung: System unter Druck. Berlin/ Germa-
ny, 05-07/03/2009 
Nachtnebel, A. (2009): „Bedingte Erstattung – Erfahrungen aus ausgewähl-
ten Ländern“, 10. Jahrestagung des Deutschen Netzwerks Evidenzbasierte 
Medizin, Evidenz und Entscheidung: System unter Druck. Berlin/ Ger-
many, 05-07/03/2009 
Radlberger, P. (2009): “Quality measurement in integrated alcoholism 
treatment models”, HTAi – Health Technology Assessment international 
Conference, 6th Annual meeting, Singapore, 21-24/ 06/2009  
 
Gyimesi, M. (2009): Application für FFG-Modsim “Mathematical Hybrid 
Modelling and Dynamic Simulation in Health Care/Healthmod”, 03/2009 
 
Falkner, E. (2009): Autologe Knorpelzelltransplantation (ACI)- Behandlung 
von Kniedefekten. HTA-Newsletter 74: 4 
Geiger-Gritsch, S. (2009): Medikamente bei Brustkrebs - Zeitliche Verzöge-
rung bis zur Volltextpublikation von Studienergebnissen. HTA-Newsletter 
74: 2 
Geiger-Gritsch, S., Nachtnebel, A. (2009): Horizon Scanning in der Onkolo-
gie - Evaluation neuer oder in Entwicklung befindlicher Krebstherapien. 
HTA-Newsletter 81: 1 (Editorial) 
Gymesi, M. (2009): Methode Modellierung – Rolle in klinischen Studien. 
HTA-Newsletter 74: 3 
poster presentations: 
4 posters 
research applications 
articles published in 
HTA newsletters 
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Gymesi, M. (2009): Kognitive Rehabilitation bei Schädel-Hirn-Trauma. 
HTA-Newsletter 77: 3 
Gymesi, M. (2009): Chemonukleolyse & intradiskale Elektrotherapie 
(IDET) zur Behandlung von diskogenen Schmerzen. HTA-Newsletter 79: 2 
Hinterreiter, G., Nachtnebel, A. (2009): CT Kolonoskopie – Screening-
methode für Kolorektalkrebs. HTA-Newsletter 74: 2 
Hinterreiter, G. (2009): Chronische Rückenschmerzen – Erfolgreiche Im-
plementierung eines Therapieangebots in Deutschland. HTA-Newsletter 
March 2009, 75: 1 (Editorial) 
Hinterreiter, G. (2009): Harninkontinenz - Verhaltenstherapie von älteren 
Menschen. HTA-Newsletter May 2009, 77: 4 
Hinterreiter, G. (2009): Transobturatorische Repositionsschlinge bei Bela-
stungsinkontinenz. HTA-Newsletter June 2009, 78: 4 
Hinterreiter, G. (2009): Perkutane Nukleotomie & Laserdiskusdekompressi-
on. HTA-Newsletter June 2009, 78: 4 
Hinterreiter, G. (2009): Individualisierte Medizin - Neue Entwicklungen in 
den Biowissenschaften. HTA-Newsletter October 2009, 81: 3 
Hintringer, K. (2009): Orphan Drugs-Politiken. Regelungen zu Arzneimit-
teln für seltene Krankheiten. HTA-Newsletter 80: 2 
Johansson, T., Hinterreiter, G. (2009): Telemedizin bei Schlaganfall. HTA-
Newsletter 79: 3 
Johansson, T., Hinterreiter, G. (2009): C-reaktives Protein als Risikomarker 
für Herzinfarktgefährdung. HTA-Newsletter 80: 3 
Johansson, T., Hinterreiter, G. (2009): Telehealth In-home Management von 
chronischen Krankheiten. HTA-Newsletter 76: 4 
Johansson, T. (2009): Antipsychotika bei Demenz. HTA-Newsletter 83: 2 
Johansson, T. (2009): Nichtmedikamentöse Behandlung bei Demenz. HTA-
Newsletter 83: 3 
Mad, P. (2009): Wehenhemmung bei drohender Frühgeburt. HTA-
Newsletter 77: 2 
Mad, P. (2009): Screening zur Vermeidung von Frühgeburten. HTA-
Newsletter 82: 4 
Mad, P. (2009):Rheumatoide- und Psoriasis-Arthritis – Relative Effektivität: 
Substanzgruppenvergleiche. HTA-Newsletter 83: 4 
Mathis, S. (2009): Neue Biomarker und Prognosemodelle für das Prostata-
karzinom. HTA-Newsletter 75: 4 
Mathis, S. (2009): EUPHORIC - Ein EU-Projekt zur (Selbst-)Evaluation von 
Leistungen in Krankenanstalten. HTA-Newsletter 77: 1 (Editorial) 
Mathis, S. (2009): IgG-Apherese bei ABO-inkompatibler Nierentransplanta-
tion. HTA-Newsletter 78:3 
Mathis, S. (2009): Evidenzbasierte Versorgung - Methoden der öffentlichen 
Versorgungsplanung. HTA-Newsletter 79: 4 
Mathis, S. (2009): Da Vinci™- System - Roboter-assistierte Chirurgie (RAC). 
HTA-Newsletter 80: 4 
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Mathis, S. (2009): Antidepressiva der 2. Generation – Relative Effektivität: 
Substanzgruppenvergleiche. HTA-Newsletter 83:2 
Nachtnebel, A. (2009): Rauchen und soziale Ungleichheit. HTA-Newsletter 
76: 2 
Nachtnebel, A. (2009): Neuropathische Schmerzen – Wirksamkeit und Ko-
steneffektivität gängiger Therapien. HTA-Newsletter 76: 3 
Nachtnebel, A. (2009): CYP2D6 Genotypisierung – Tamoxifentherapie bei 
Brustkrebs. HTA-Newsletter 77: 2 
Nachtnebel, A. (2009): Injektions- und Radiofrequenztherapien bei chroni-
schen Rückenschmerzen. HTA-Newsletter 78: 2 
Nachtnebel, A. (2009): Bildgesteuerte Strahlentherapie mittels Cone-Beam 
CT. HTA-Newsletter 78: 3 
Patera, N. (2009): Mammographie-Screening Benchmarks- Evaluationser-
gebnisse organisierter Programme. HTA-Newsletter 81: 2 
Piso, B. (2009): Soll ich oder soll ich nicht? Resümee des Entwicklungspro-
zesses einer HPV-Entscheidungshilfe. HTA-Newsletter 76: 1 (Editorial) 
Piso, B. (2009): PECLA - Pumpless extracorporeal lung assist. HTA-
Newsletter 78: 2 
Radlberger, P. (2009): Alkoholtherapie – Evaluierung integrierter Versor-
gungsmodelle. HTA-Newsletter 75: 2 
Radlberger, P. (2009): Medikamentenbeschichtete Ballonkatheter bei koro-
naren Herzerkrankungen. HTA-Newsletter 78: 2 
Radlberger, P. (2009): Kinder- und Jugendpsychiatrie - Gesundheitsökono-
mische Bewertung. HTA-Newsletter 82: 3 
Schumacher, I. (2009): Lebensmittelfarbstoffe und Hyperaktivität – Besteht 
ein Zusammenhang? HTA-Newsletter 81: 2 
Warmuth, M. (2009): Gendoping: Leistungssteigerung, Gesellschaftstrend & 
Anti-Aging. HTA-Newsletter 80: 3 
Warmuth, M. (2009): Sprachscreening: Diagnostik und Therapie bei Ent-
wicklungsstörungen. HTA-Newsletter 82:2 
Wild, C. (2009): Influenza – Impfung und kausale Therapie. HTA-
Newsletter 75. 1 (Editorial) 
Wild, C., Busley, A. (2009): Deutsch-Österreichische Kooperation in der 
Bewertung Medizinischer Einzelleistungen. HTA-Newsletter 78: 1 (Editori-
al) 
Wild, C. (2009): Intraoperative Radiotherapie bei primären Brustkrebs. 
HTA-Newsletter 78: 3 
Wild, C. (2009): Pandemie: Vogelgrippe, Schweinegrippe, Menschengrippe. 
HTA-Newsletter 79: 1 (Editorial) 
Wild, C. (2009): Dis-Investment: Ausschluss von Interventionen aus Lei-
stungskatalogen. HTA-Newsletter 80: 1 (Editorial) 
Wild, C. (2009): Surrogatparameter und PatientInnenrelevante Endpunkte – 
Annahmen oder Validierung? HTA-Newsletter 81: 3 
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Winkler, R. (2009): Verteilungsgerechtigkeit von Gesundheitsleistungen. 
HTA-Newsletter 74: 1 (Editorial). 
Winkler, R. (2009). Kinder- und Jugendpsychiatrie. Indikatoren und In-
strumente zur Evaluierung. HTA-Newsletter 82: 2. 
Zechmeister, I. (2009): Demenzerkrankung: Was können pflegerische Ver-
sorgungskonzepte. HTA-Newsletter 75: 3 
Zechmeister, I. (2009): Leitlinien zur entscheidungsanalytischen Modellie-
rung: Qualitätssicherung für die Forschung. HTA-Newsletter 76: 2 
Zechmeister, I. (2009): Mutter-Kind-Pass: Betreuung von Schwangeren im 
internationalen Vergleich. HTA-Newsletter 79: 2 
2.3 Participation in Scientific Meeetings 
February: 
„Gewalt an Kindern und ihre Darstellung in den Medien“; Fachkonferenz an 
der Sigmund‐Freud Privatuniversität Vienna, 16/02/2009 (Roman Winkler) 
„Verstehen  wir  einander  noch?  Kinder‐  und  Jugendpsychiatrie  unter  Be‐
schleunigungsbedingungen.  26.  Jahrestagung  der Österr. Gesellschaft für 
Kinder- und Jugendpsychiatrie. Krems a.d. Donau, 26-28/02/2009 (Roman 
Winkler) 
March: 
LBI-HTA Tagung 'FairHealth: Verteilungsgerechtigkeit und Ressourcenal-
lokation von öffentlichen Gesundheitsleistungen', Urania Vienna, 
02/03/2009 (Smiljana Blagojevic, Michael Gyimesi, Katharina Hintringer, 
Gerda Hinterreiter, Stefan Mathis, Tarquin Mittermayr, Anna Nachtnebel, 
Philipp Radlberger, Brigitte Piso, Roman Winkler, Claudia Wild, Ingrid 
Zechmeister) 
11. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin. Evi-
denz und Entscheidung: System unter Druck. Berlin/ Germany, 05.-
07/03/2009 (Smiljana Blagojevic, Rosemarie Felder-Puig, Gerda Hinterrei-
ter, Stefan Mathis, Tarquin Mittermayr, Brigitte Piso, Philipp Radlberger, 
Claudia Wild, Roman Winkler) 
6. Forum Hospital Management. "Das Patienten-Krankenhaus - Eine Reise 
in die Zukunft". Forum Alpbach, 19/03/2009 (Claudia Wild) 
April: 
Hot doc: Schutz oder Schaden? Die Wirkung von Impfungen auf den 
menschlichen Körper; Ärztekammer für Wien; Vienna, 01/04/2009 (Brigitte 
Piso) 
GesundheitsPiazza Bodensee, GesundheitsPiazzaZwei, Bregenz, 02-
03/04/2009 (Claudia Wild) 
Symposium „Sprechen Sie Gesundheit“ Kommunikation im Gesundheits-
wesen- Planung oder Zufall? Österreichische Akademie für Präventivmedi-
zin und Gesundheitskommunikation; Vienna, 23-24/04/2009 (Brigitte Piso) 
conferences and 
congresses 
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May: 
Jahresforum „Konfrontation Gesundheit“ Business Circle; Vienna, 14-
15/05/2009 (Brigitte Piso, Claudia Wild) 
June: 
Press conference „Hormonersatztherapie“, Presseclub Concordia, Vienna, 
19/06/2009 (Gerda Hinterreiter) 
HTAi – Health Technology Assessment international Conference, 6th An-
nual meeting, Singapore, 21-24/06/2009 (Anna Nachtnebel, Philipp Radl-
berger) 
Europäische Kongress für evidenzbasierte Prävention; Baden bei Wien, 24-
26/6/2009 (Gerda Hinterreiter, Tim Johansson, Philipp Mad, Brigitte Piso, 
Claudia Wild, Roman Winkler) 
September: 
Jahrestagung der Arbeitsgemeinschaft für Medizinisches Bibliothekswesen 
(AGMB) e.V. „Medizinbibliotheken: Leuchttürme im Meer elektronischer 
Informationen“, Hamburg/Germany 07-09/09/2009 (Tarquin Mittermayr) 
JournalistInnenseminar „Pandemieimpfung 2009 – eine europäische Her-
ausforderung“, Ethik-Kommission der Medizinischen Universität Wien,  
Vienna, 22/09/2009 (Gerda Hinterreiter) 
11. Wissenschaftliche Tagung der Österreichischen Gesellschaft für Public 
Health „Migration, Kultur und Gesundheit: Chancen, Herausforderungen 
und Lösungen“, Linz/Austria, 24-25/09/2009 (Brigitte Piso, Katharina Hin-
tringer, Marisa Warmuth) 
12. European Health Forum Gastein “Financial Crisis and Health Policy”, 
Bad Hofgastein/Austria, 29/09 -03/10/2009 (Philipp Radlberger)  
8. Deutscher Kongress für Versorgungsforschung des Deutschen Netzwerks 
Versorgungsforschung e.V. (DNVF) und 43. Kongress der Deutschen Gesell-
schaft für Allgemeinmedizin und Familienmedizin e.V. (DEGAM), Heidel-
berg/ Germany, 30/09 - 02/10/2009 (Stefan Mathis)  
October: 
KKSN (Koordinierungszentren für Klinische Studien - Netzwerk) Symposi-
um. Versorgungsnahe klinische Studien nach der Zulassung, Freiburg/ Ger-
many, 08-09/10/2009 (Stefan Mathis) 
Politische Kindermedizin; Salzburg, 16.-17.10. 2009 (Roman Winkler) 
Symposium der Österreichischen Ärztekammer und des Europäischen Fo-
rums Alpbach „Herausforderung Humanität: Medizin und Ethik“, Vienna, 
23/10/2009 (Philipp Radlberger)  
ISPOR - 12th Annual European Congress, Paris, 24-27/10/2009 (Michael 
Gyimesi) 
Linzer  Forum  09  „[In]transparenz  –  Ein‐Blick  in  das  Gesundheitswesen“, 
MED Ausbildungszentrum,  AKH  Linz,  29/10/2009  (Gerda Hinterreiter,  Ro‐
man Winkler) 
Ernst Strüngmann Forum: „Better Doctors, Better Patients, Better Decisions 
Forschung 
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Envisioning Health Care 2020“. FIAS/ Universität Frankfurt, 25.-
31./10/2009 (Claudia Wild) 
November: 
Internationale Fachtagung SciCom 09 “Aufklärung, Dialog oder Event? An-
forderungen an eine zielgruppenorientierte Wissenschaftskommunikation“, 
Technische Universität Wien, Vienna 16.-17/11/2009 (Gerda Hinterreiter) 
1. Erlanger Telemedizin Symposium. SchlaganfallNetzwerk mit Telemedi-
zin in Nordbayern (STENO), Erlangen/Germany, 22/11/2009 (Tim Johans-
son) 
Pharmaökonomie Workshop;  IPPR Konferenzreihe, VIenna, 25‐27/11/2009 
(Claudia Wild, Roman Winkler) 
Pressegespräch Gesundheit Österreich GmbH, Vienna, 25/11/2009 (Gerda 
Hinterreiter, Marisa Warmuth) 
Neue Entwicklungsmöglichkeiten der Telemedizin an den Salzburger Lan-
deskliniken (Produktpräsentationen), Salzburg, 30/11/2009 (Tim Johansson) 
December: 
team up! -1. eHealth Day Salzburg, eHealth Salzburg 2014 - Potenziale, 
Trends & Strategien, Salzburg, 02/12/2009 (Tim Johansson) 
EUnetHTA “HTA Methodology Conference”, Stockholm/Schweden, 
03/12/2009 (Claudia Wild) 
Policy Makers Forum: PharamacoEconomics. Karolinska Universität. Stock-
holm/Schweden, 04/12/2009 (Claudia Wild) 
Health Technology Assessment World - Europe 2009. London/ UK, 08-
11/12/2009 (Anna Nachtnebel) 
ExpertInnentagung des Fonds Gesundes Österreich „Gesundheitsförde-
rungsforschung in Österreich. Aktuelle Entwicklungen und Zukunftsthe-
men“, Wien, 14/12/2009 
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3 Scientific Co-operations 
EUnetHTA Founding Partners face-to-face meeting, Copenhagen/Denmark, 
24/03/2009 (Claudia Wild) 
EUnetHTA face-to-face meeting, Brussels/Belgium, 20/02/2009 (Claudia 
Wild) 
EUnetHTA Plenary Assembly face-to-face meeting, Sevilla/Spain, 28.-
29/09/2009 (Gerda Hinterreiter) 
EUnetHTA Executive Committee face-to-face meeting, Stockholm/ Sweden, 
02/12/2009 (Gerda Hinterreiter) 
EUnetHTA Founding Partners e-meeting, 05/02/2009, 10:00–11:30 (Claudia 
Wild, Gerda Hinterreiter) 
EUnetHTA Founding Partners e-meeting, 03/03/2009, 10:00–11:30 (Claudia 
Wild) 
EUnetHTA e-meeting, 05/03/2009, 10:00–12:00 (Claudia Wild)  
EUnetHTA Collaboration e-meeting, 21/04/2009, 10:00–12:30 (Gerda 
Hinterreiter) 
EUnetHTA Joint Action e-meeting, 12/05/2009, 10:00–12:00 (Claudia Wild, 
Gerda Hinterreiter) 
EUnetHTA Collaboration e-meeting, 09/06/2009, 10:00–12:30 (Claudia 
Wild, Gerda Hinterreiter) 
EUnetHTA Executive Committee e-meeting, 08/09/2009, 14:00–16:00 
(Claudia Wild, Gerda Hinterreiter) 
EUnetHTA Executive Committee e-meeting, 06/10/2009, 14:00–15:30 
(Claudia Wild) 
EUnetHTA e-meeting, 10/11/2009, 13:00–15:00 (Gerda Hinterreiter) 
EUnetHTA WP6/A & WP7/B e-meeting, 10/12/2009, 10:00–11:00 (Claudia 
Wild, Gerda Hinterreiter, Marisa Warmuth, Stefan Mathis) 
EUnetHTA Founding Partners e-meeting, 15/12/2009, 13:00–14:30 (Claudia 
Wild, Gerda Hinterreiter) 
EuroScan meeting, Helsinki/Finland, 23-24/03/2009 (Anna Nachtnebel) 
EuroScan meeting, Madrid/Spain, 23-24/11/2009 (Anna Nachtnebel) 
2nd session of the working group regarding registers of the DNVF, „Mediz-
inische Register“, Cologne, 24/06/2009 (Stefan Mathis) 
3rd session of the working group regarding registers of the DNVF, Heidel-
berg, within the German Kongress for Health Services research of the Ger-
man Network for Health Services Reasearch (DNVF e.V.) and the 43rd 
Kongress of the German Society for General and Family Medicine (DEGAM 
e.V.), Heidelberg, 30/09 -02/10/2009 (Stefan Mathis) 
MEL/NUB cooperation with the „Medizinischen Dienst des Spitzenverban-
des Bund der Krankenkassen (MDS)“, Dr. Annette Busley, Germany (Clau-
EUnetHTA  
face-to-face meetings  
EUnetHTA  
e-meetings 
EuroScan meeting 
other cooperation 
meetings 
other international  
cooperations 
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dia Wild)  
Dr. Ilse Reiner-Theisen within the MEL/NUB cooperation with the „Medi-
zinischer Dienst der Spitzenverbände (MDS)“, „Medikamentenbeschichtete 
Ballonkatheter“ (Philipp Radlberger) 
Dr. Anna BUCSICS, Hauptverband der Österr. Sozialversicherungsträger, 
Department of Evidence Based Economic Healthcare, Vienna; Dr. Michael 
POBER, Hospital St. Pölten, Hemato-Oncology, NÖ Landeskliniken Hol-
ding; Dr. Johannes ANDEL, State Hospital Steyr, Oncology and Public 
Health, GESPAG, OÖ; Mag. Andreas SEIRINGER, State Hospital Vöckla-
bruck, Head of the Hospital Pharmacy – Pharmacist, GESPAG, OÖ; Prim. 
Dr. Peter KRIPPL, State Hospital Fürstenfeld – Hematology and Oncology, 
KAGES, Steiermark; Dr. Wolfgang WILLENBACHER, State Hospital 
Innsbruck University Hospital, Hemato-Oncology, TILAK, Tirol; Mag. 
Sigrid KIENDLER, State Hospital Innsbruck – Deputy Head of the Hospi-
tal Pharmacy – Pharmacist, TILAK, Tirol; Dr. Clemens LEITGEB, Wil-
helminenspital - Oncology and Hematology, KAV ,Wien – all of them within 
the project „Horizon Scanning in Oncology“ (Sabine Geiger-Gritsch, Anna 
Nachtnebel, Katharina Hintringer) 
Dr. Felix Fischer, senior consultant at the therapy center Traun of the Wag-
ner-Jauregg psychatric clinic Linz, as well as Dr. Oliver Scheibenbogen, sen-
ior physician at the Anton Proksch Institute Kalksburg, within the project 
„Alkoholtherapeutische Versorgung III“ (Philipp Radlberger) 
Prim. PD Dr. Leonhard Thun-Hohenstein, leader of the University De-
partment of Child and Adolescent Psychiatry in Salzburg, within the context 
of the evaluation project „Child and Adolescent Psychiatry Salzburg“ (Ro-
man Winkler) 
UMIT – University for Health Sciences, Medical Informatics and Technol-
ogy, Hall i. T.l; Organisation of the annual collaboration meeting (exchange 
of methodology and content) from 28 -29/09/2009 in Dorfgastein/Sbg. 
DUK – Danube University Krems, Department Clinical and Evidence based 
Medicine (exchange of methodology and content). 
Cooperation with the University of Oslo, Imperial College London, Norwe-
gian Knowledge Centre for the Health Services and UMIT – University for 
Health Sciences, Medical Informatics and Technology: 
Zechmeister, I., Freiesleben de Blasio, B., Garnett, G., Neilson A., Siebert, 
U. (2009): Cost-effectiveness analysis of human papillomavirus vaccination 
programs to prevent cervical cancer in Austria. Vaccine 27(37):5133-41  
Zechmeister, I., Freiesleben de Blasio, B., Garnett, G. (2009): HPV-
vaccination for the prevention of cervical cancer in Austria: A model based 
long-term prognosis on cancer epidemiology. Journal of Public Health 
‘Online first Publication’, 11/08/2009 
http://www.springerlink.com/content/n46275377p88w256/?p=555c2259b16f
431cb36118009b326439&pi=0 
In 2009, the following external authors could be encouraged to contribute 
(e.g. Editorials) to our HTA-Newsletter: 
 
national cooperation 
cooperation within 
publication projects 
other cooperations 
Scientific Co-operations 
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b Dr. Annette Busley, Medizinischer Dienst des Spitzenverbandes 
Bund der Krankenkassen/Germany (HTA-Newsletter 78: 1) 
b Ao.Univ.-Prof. Dr.med. Christian Popow, Department of Child 
and Adolescent Psychiatry, Medical University of Vienna, Univer-
sity Hospital Vienna (HTA-Newsletter 82: 1) 
b Dagmar Lühmann, MD, Department of Social Medicine, Univer-
sity hospital Schleswig-Holstein/Germany (HTA-Newsletter 83: 1) 
Research and project activities at the University Department of Child and 
Adolescent Psychiatry at the Christian-Doppler-Clinic in Salzburg, 13-
24/07/2009 (Roman Winkler).  
 
 
academic exchange  
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4 Other Activities 
Claudia Wild was teaching at  
b the Masters’ course „Public Health“ at the Medical University of 
Graz (campuses Graz and Dornbirn), 
b the postgraduate course „Public Health & Health Care Manage-
ment“ at the Johannes Kepler University Linz , 
b the Masters’ course „Health Sciences“ at the Private University for 
Health Sciences, Medical Informatics and Technology (UMIT) in 
Hall/Tyrol, 
b the Masters’ course „Health Care Management“ at the Carinthia 
University of Applied Sciences,  
b the HTA postgraduate course at the Department for Evidence-based 
Medicine and Clinical Epidemiology at the Danube-University and 
also at 
b the medical advanced training academy (MedAK) in Linz. 
Ingrid Zechmeister gave a lecture on „Economic evaluation in health care” 
at the Danube-University Krems (07.10.2009). 
Since 2009, Michael Gyimesi has been teaching „Modelling & Simulation 
within Health Technology Assessment (HTA)“ as a guest lecturer at the 
Technical University of Vienna. 
In 2009 Claudia Wild reviewed manuscripts for the “German Journal for 
Evidence and Quality in Healthcare“ (ZEFQ), “Health Policy” and Interna-
tional Journal of Technology Assessment in Health Care (Int J TAHC).  
Ingrid Zechmeister was engaged in reviewing for the „Journal of Public 
Health“.  
The following diploma- and master theses were supervised by senior re-
searchers, and supported by library services in 2009: 
b Bernhard Fleischner (Institute for Health Care Engineering, 
Technical University Graz): „Beschaffungsprozesse ausgewählter 
Produktgruppen in Krankenanstalten“ – Claudia Wild 
b Ines Schumacher B.A. (Masters’ cours for Public Health and Nurs-
ing Sciences, Universityt Bremen): „Machen Farbstoffe in Nah-
rungsmitteln hyperaktiv?“ - Claudia Wild 
Ongoing supervision of master theses:  
b Mag. Harald Keckeis (Masters’ cours for Public Health, University 
Graz): „HTA als Controlling–Instrument“ - Claudia Wild  
b Muna Abuzahra (Masters’ course Health Care Management, 
Carinthia University of Applied Sciences): “Der Einsatz von 
Messinstrumenten zur Schweregraddifferenzierung in der Neuro- 
und Traumarehabilitation in Österreich” - Brigitte Piso 
 
teaching 
expert & referee 
activities 
supervision of diploma 
and doctoral theses 
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5 Prospects 
2009 was largely shaped by preparations for the interim evaluation and the 
follow-up work required by the extension of contracts with partners. Fur-
thermore, the reorganisation of the Institute by means of the introduction of 
a middle management level and corresponding heads of department allevi-
ated the Institute’s management of some of its operational activities. At the 
same time, the maternity leave of two researchers required the redistribution 
of tasks in individual areas of work. 
The “National HTA Strategy” envisaged by the ministry for health and 
commissioned from the GÖG/ Gesundheit Österreich GesmbH is likely to 
heighten the profile of the LBI-HTA. 
The challenges for 2010 will be the focus of the Institute’s management on 
strategic tasks and the preparation for an application for a second cycle of 
the LBI-HTA within the Ludwig Boltzmann Association framework. 
 
challenges in 2010 
